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ABSTRACT 
Bacterial contamination of blood products presents an ongoing 
challenge to transfusion therapy. Contaminating bacteria are typically 
introduced in low numbers at the time of collection, but can proliferate during 
storage to reach >109 colony forming units/mL (CFUhnL). The consequences 
of contamination include product wastage and transfusion-transmitted sepsis, 
but in Australia screening is conducted on only 1% of products by a slow and 
labour-intensive culture method. Accordingly, there is a need for a more 
practicable and rapid assay. The purposes of this study were to investigate the 
growth kinetics of bacteria in stored products, and to develop a rapid method to 
detect them. 
Pseudomonas, Staphylococcus and Yersinia species were inoculated 
into buffy coat platelet concentrates (PCs) and red cell concentrates (RCCs) at 
10, 102 or 103CFU/mL and then stored at 22 ± 2°C, agitated for PCs, or at 4 ± 
2°C, stationary for RCCs. Bacterial growth was monitored by plate count, and 
product spoilage (clumping or haemolysis) was noted. Even at the lowest 
inoculum, all bacterial species grew rapidly in PCs, although clumping was not 
observed until 3 to 5 days (>107 CFU/mL). In RCCs, all species were 
recovered after 36 days, but only P. fluorescens and Y. enterocolitica 
proliferated, reaching >10 7 CFU/mL before causing haemolysis. 
To detect bacterial contamination, we developed a PCR-based assay. A 
method using bead-beating and spin column purification extracted bacterial 
DNA from the densely cellular blood products in under 30 minutes. Using this 
template and primers targeting conserved regions of the bacterial 16S rRNA 
gene, a 1361-bp fragment was amplified from >30 bacterial species and strains 
tested at less than 10 3 CFU/mL in all sample types. Examination of the PCR 
product using Southern blotting with specific oligonucleotide probes revealed 
that identification of the bacteria was also possible. Evaluation of this 
methodology using stored specimens from the kinetic study, showed that 
bacteria which had grown in blood products could be detected in 2 to 3 days 
iv 
for PCs and in 6 to 9 days for RCCs. Whilst these results matched our 
preferred time-frame, the sensitivity of detection was reduced in comparison to 
directly spiked samples. This reduced sensitivity may have been a consequence 
of long-term storage of the test samples. 
In conclusion, this study has shown that screening of blood products for 
bacteria using a universal PCR is feasible and practicable, and can be 
performed within a time frame required by the transfusion industry. 
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1.1 Development of modern blood banking 
The first blood transfusion was performed by a physician named Richard 
Lower in 1665. It followed the discovery of the circulatory system by William 
Harvey in 1628. Lower demonstrated with dogs that a recipient drained of its own 
blood had restored vitality when transfused with blood from another dog. However, 
50 % of the first human to human blood transfusions conducted by James Blundell, 
failed. It was not until after the introduction of antiseptics by Joseph Lister in 1867 
and Karl Landsteiner's Nobel Prize winning discovery of the ABO blood grouping 
system in 1907, that transfusion therapy advanced sufficiently for widespread 
application. From 1916 to 1950, many of the standard storage and typing procedures 
used today were developed. The first blood depots with professional donors were 
established in 1916. These utilised the first citrate-based anticoagulant in transfusion 
media. This anticoagulant prolonged blood storage and transfusion times and 
eliminated the need for direct suturing of donor and recipient veins for a successful 
transfusion. The use of Rhesus (Rh) typing in conjunction with ABO grouping 
eliminated a majority of transfusion reactions. The plastic bag collection system, 
implemented in 1950 to supersede open glass bottle systems, enabled the safe 
collection and preparation of multiple blood components (such as plasma and red cell 
products) from a single whole blood (WB) donation (67, 157, 191). Division of WB 
not only enabled specific treatment of blood loss or disorders, but increased the 
recipient to donor ratio by providing multiple products from a single donation. This 
is particularly beneficial with rare blood type donations where donors are scarce, as it 
is common for treatment to require multiple applications of one type of product. 
Storage of platelet concentrates (PCs) at 22 ± 2 °C and red cell concentrates (RCCs) 
at 4 ± 2°C became standard, increasing the maximum storage duration of these 
products with a minimal loss of viability. Today, transfusion therapy is an important 
part of medicine and saves thousands of lives each year. 
Thus, with most of the past transfusion problems overcome, blood services 
such as the Australian Red Cross Blood Service (ARCBS) now provide a range of 
products that are under increasing demand. 
Blood banking continued essentially unchanged in theory and practice until 
the early 1980s, when the dramatic appearance of human immunodeficiency virus 
(HIV) in the blood supply demonstrated the need for continued vigilance of 
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donations in order to protect transfusion recipients and clinical and laboratory staff. 
Previously undisclosed transfusion risks such as the recent concern regarding the 
potential for transmission of variant Creutzfeldt-Jacob disease (vCJD, an infectious 
protein prion disease) continue to emerge. In light of these emerging threats to the 
blood supply, recent research and development has shifted toward techniques for the 
detection of infective blood-borne microbes in order to improve the safety of blood 
products and transfusion medicine. Today, viral screening of blood donations is 
extensive (discussed further in Section 1.4.1). 
The incidence of transfusion-transmitted viral infections has declined since 
the introduction of screening measures, but the transmission of bacterial pathogens 
has remained constant (39, 103). Based on data obtained from haemovigilance 
programs in the USA (the Bacterial Contamination study — BaCon), the UK (the 
Serious Hazards Of Transfusion study - SHOT), and France, and from other fatality 
reports, the risk of bacterial contamination and mortality following transfusion, far 
outstrips the contamination and mortality rate of screened viruses (63, 83, 116, 118, 
175). Haemovigilance programs have yet to be undertaken in Australia, but such 
reports from elsewhere show bacterial contamination is a global concern. Despite 
this higher risk, bacterial contamination of blood products has not attracted the same 
attention as viral risks. The reasons for this seeming inequity are varied and 
complex, but in part are due to technical limitations of bacterial screening (as 
discussed in Section 1.7). 
Although closed blood collection systems initially reduced the frequency of 
bacterial contamination, developments in the preparation and storage of blood 
components to prolong shelf-life, potentially facilitate the proliferation of many 
bacterial contaminants, should these be present in the product (67, 157). Despite 
this, the widely accepted practice throughout the developed world is to screen only 
1% of all blood products as part of a routine quality control program. Typically, 
screening relies on a culture method that may take several days for a result (Section 
1.4.4). With no established rapid test for rigorous detection of bacteria in blood 
products, immunocompromised patients in particular are at risk of a severe septic 
reaction or death, should they receive a bacteria-contaminated product. It is clear 
that whilst recipients remain vulnerable to potentially fatal microbial contaminants, 
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the need for the development of improved rapid, specific and sensitive methods to 
detect bacteria in blood products is critical. 
In order to address the issue of bacterial detection in blood products, it is 
important to clearly understand the WB collection process and the manufacture and 
storage of blood products themselves. This is described below, with particular 
emphasis on identifying the points in the collection and manufacturing process of 
blood products where bacteria may inadvertently be introduced. 
1.2 Blood collection, product preparation and storage 
The following sections detail the pre-donation questionnaire, the collection 
and manufacture of WB into the various blood products and their subsequent storage. 
These procedures, followed by the ARCBS, are based upon standards set by the 
Council of Europe (56). 
1.2.1 Pre-donation and blood collection procedure 
Prior to venepuncture at the antecubital site (phlebotomy), donors are asked a 
series of questions regarding their general health, their travel, history of injectable 
drugs, unsafe sexual practices, etc. These questions allow assessment of donor 
fitness and potential for carrying any unwanted transmissible agents. Donations are 
not accepted from donors deemed unsuitable. 
The phlebotomist is required to check the donor's blood pressure and heart 
rate before preparing the venepuncture site with a comprehensive sterile swab of 
70% isopropanol. Percutaneous phlebotomy of the antecubital vein is performed 
aseptically with a single-use needle conjoined to a second sheathed needle in a 
surrounding needle guard, which facilitates the removal of a small quantity of blood 
for quality control and viral screening purposes (Sections 1.3 and 1.4). The donation 
is then taken from the same venepuncture apparatus via a single tube connected to 
the collection bag. 
WB donations are the most common form of blood donation, although 
collection of separate blood fractions (i.e. plasma, red blood cells or platelets) by 
apheresis also occurs. About 450 mL of WB is collected into a blood collection pack 
containing citrate-phosphate-dextrose anticoagulant. Different pack configurations 
are available depending on the type of processing and blood components to be 
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prepared. For example, 'top-and-bottom' packs (e.g., Optipacs, Baxter Fenwal, La 
Chatre, France) are used for the preparation of buffy-coat depleted products. During 
the donation, the blood is mixed with citrate-phosphate-dextrose-adenine (CPD-A1) 
anticoagulant contained in a collection bag that is cradled by a gently rocking 
mechanism that can detect a blood volume of 450 mL ± 10% by weight. Collection 
is usually completed in 10 to 20 min. If the collection time exceeds 15 min, the 
plasma component is considered unsuitable as a source of Factor VIII coagulation 
protein, and is assigned for other uses. All other components are however retained 
for normal processing. The bag of WB is then processed into separate components 
(Sections 1.2.2 and 1.2.3). 
Early transfusion therapy depended solely upon WB, yet now this is not 
considered the most appropriate product in the treatment of a wide range of patient 
needs and is rarely used. Modern transfusion therapy seeks to target treatment to the 
clinical requirements of each recipient, using separated blood components. The 
major products produced by this method are RCCs, PCs, and fresh frozen plasma 
(1.1.P). This allows the direct application of the appropriate product such as RCCs in 
the treatment of anaemia (191). The methods for preparing these components are 
reviewed below. 
1.2.2 Platelet-rich plasma method of preparation of blood products 
The platelet-rich plasma (PRP) method is the longest used method of 
component preparation, and is utilised in the USA, and at some ARCBS facilities. 
The WB is collected and centrifuged at 640 xg to separate the plasma and red blood 
cells (RBCs), the latter of which is expressed into a new component bag as a finished 
RCC. Final PRP RCCs contain a maximum of 0.2 to 1 x10 9 (ARCBS standards) 
white blood cells (WBC)/unit. The platelet-rich plasma is further processed at 1000 
xg to separate the cellular platelet portion from the plasma. The final PRP PC 
contains 0.05 to 1 x109 WBCs per single unit equivalent (they can be pooled 
together) (56). 
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1.2.3 Buffy coat method of preparation of blood products 
The buffy coat method is widely used for blood product preparation in 
Australia, and also is used extensively throughout Europe for reasons detailed below. 
Separation of blood components by the buffy coat method is depicted in Figure 1.1. 
The WB is collected into 'top and bottom' packs and is centrifuged at 5 000 xg for 
10 min, and the RCCs and FFP are expressed into separate satellite bags using an 
automated blood component separator (e.g., Optipress, Baxter) leaving the platelet-
rich buffy coat in the primary pack. Buffy coats contain 50 to 70% of leukocytes 
from the initial WB donation, and a small percentage of RBCs in addition to the 
platelet fraction (56). The RBCs are resuspended in 100 mL storage solution (e.g., 
Adsol solution, Baxter Fenwal, Deerfield) making a finished RCC. PCs are prepared 
by pooling four or five ABO and Rh compatible buffy coats into a platelet bag (e.g., 
PL2410 bag, Baxter). These are then resuspended in 300 mL plasma or platelet 
additive solution (e.g., T-sol®, Baxter Fenwal), and re-centrifuged at 2 000 xg for 2 
to 3 min. The platelet-rich portion of the buffy coat is siphoned into a fresh bag, and 
the remaining leukocyte-rich fraction is discarded. The final PCs contain 
approximately 8 x10 7 WBC/unit, whilst RCCs contain around 10 8 WBC/unit (56). 
The advantages of the buffy coat method over other WB separation procedures such 
as the PRP method, include a reduction in leukocyte contamination and red cell 
aggregation and an increased recovered platelet yield from the buffy coat (56). The 
standard blood products can be further processed into what are known as 'boutique' 
blood components (e.g., passed through a WBC-removal filter to deplete these to less 
than 106 WBC/unit) which are usually manufactured upon request. 
This thesis shall focus on the standard cellular blood products produced by 
the buffy coat method (i.e., PCs and RCCs) as these are most risk of high levels of 
contamination, they are most commonly used in Australia, and little is known about 
how bacteria behave in these during storage. However, it is anticipated that detection 
methods produced by this work shall be applicable to all blood product types. 
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Figure 1.1: Diagrammatic representation of the method 
used to derive buffy coat blood products 
EVF — Erythrocyte or cellular volume fraction 
1.2.4 Storage of blood products 
Separating WB into products by the buffy coat method, results in products 
with distinctly different cellular contents and hence, potential applications. 
Component preparation also facilitates optimal product storage for the viability of the 
unique cellular content of each. Blood collection and storage uses anticoagulants 
that contain buffered citrate to prevent coagulation, and dextrose (glucose) as an 
energy source to maintain cell viability and extend the shelf-life of the product (56). 
Other additives in anticoagulants and storage solutions include adenine and 
phosphate, as will be detailed in the sections following. 
	
1.2.4.1 	Fresh frozen plasma (FFP) 
H-T is frozen under conditions that will maintain its labile coagulation factors 
in a functional state (56). As HP is stored at sub-zero temperatures (usually -25°C 
or less), the concerns related to 14141' are contamination with cellular and viral matter 
rather than transfusion-transmitted bacterial sepsis (TTBS). TTBS following 
transfusion of FFP is a rare occurrence in comparison to products stored in the liquid 
state, notably PCs and RCCs. 
1.2.4.2 	Red cell concentrates 
Storage at 4± 2°C in Adsol storage solution permits up to 42 days of RCC 
viability. There are, however, a number of considerations that arise by this length of 
storage. The acidity increases over time, reducing glycolysis and the content of 
adenosine nucleotides (ATP, adenosine di-phosphate [ADP], and adenosine mono-
phosphate [AMP]), essential for cell membrane and transport functions. The latter 
has been addressed by the addition of adenine to the storage solution, which as the 
main component of the adenosine nucleotides allows the RBC to synthesise new 
nucleotides to compensate for the losses incurred. Aggregate formation by platelets 
and leukocytes (microaggregates), require product filtering at the point of transfusion 
and the oxygen-carrying capacity of the red blood cells decreases (56). The duration 
and temperature of RCC storage, and their high iron content provide suitable 
conditions for the proliferation of psychrophilic bacteria (organisms capable of 
growing at less than 4°C)(200). This concern is considered in greater detail in 
Section 1.5.2. 
8 
1.2.4.3 	Platelet concentrates 
PCs, such as those produced by the buffy coat method present the greatest 
challenge of modem blood collection, as they require storage at 22 ± 2 °C and 
continuous oxygenation to ensure component viability and longevity. Furthermore, 
the pooling of buffy coats increases the chances of contamination of the final PC. 
PCs are also manufactured by apheresis, which allows collection of one 
platelet donation from a single donor. It involves the separation and retention of the 
platelet component from WB whilst the remainder of the blood is returned to the 
donor. All apparatus that is in direct contact with the donor blood during the 
collection is for single use only and is sterile and disposable. This eliminates the 
possibility of donor and product cross-infection via the apheresis machinery. The 
pre-donation questionnaire and the selection of platelet donors are identical to those 
used for WB donors. Apheresis requires a single donation over a one hour period. It 
produces number of platelets equivalent to PCs such as those produced by the pooled 
buffy coat method. Despite the improved platelet yield and the purported reduction 
in the frequency of bacterial contamination (138, 145, 146, 225), apheresis PCs are 
not produced as frequently as buffy coat PCs. This is due to the considerably higher 
expense involved in apheresis collection, the longer time required for the donation, 
and the limitation that just one product is obtained by this method as opposed to the 
three by the standard buffy coat method. Storage of apheresis single donor and 
pooled buffy coat PCs is identical (56). For the purposes of this thesis, the 
abbreviation PC will simply refer to both apheresis and buffy coat methods of 
production of PCs. 
Under the described storage conditions, platelets maintain viability and 
function for seven days, but storage is currently limited to five days (132). This is 
due to safety concerns, because if bacterial contaminants are present there is a 
significant risk of high bacterial load after seven days of storage. Bacterial 
contaminants were most commonly found in significant numbers after five days of 
storage, causing a significant number of episodes of TTBS (34). Consequently, in 
1986 the Food and Drug Administration (FDA) in the USA limited the storage of 
PCs to a maximum of five days in order to reduce the incidence of PC-related TTBS 
(6). As the main focus of this thesis, the problem of bacterial contamination in the 
context of PCs and RCCs will be described in greater detail in Section 1.5.2. 
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1.3 Product quality control 
Quality control of product content is conducted at the ARCBS on two levels: 
mandatory screening of blood donors and representative portion screening of 
manufactured blood products. Mandatory screening is predominantly conducted 
immediately following the collection process, and includes ABO grouping, 
haemoglobin content, and targeted viral screening (detailed in Section 1.4). 
Approximately 1% of each product type is screened for other qualities, such as 
Factor Via content in FFP (Table 1.1). 
1.4 Microbial screening 
As mentioned in Section 1.1, the screening of blood donations has been 
developed and implemented for the protection of the recipient and staff, and to 
ensure the integrity of the blood supply. The screening methodology for each 
category of contaminant varies depending on the nature and physical structure of the 
contaminant concerned, and the relative ease, speed, specificity and sensitivity with 
which each may be detected. Extensive testing methodologies are now available for 
viral contaminants. However, the methodologies for detecting bacterial and 
protozoan contaminants have been less rigorously developed. 
The major focus of this thesis is the bacterial contamination of blood products. 
Hence, although it will be discussed briefly here (screening for Syphilis and generic 
bacterial screening), it will be covered in greater depth in Section 1.5 onwards. 
The following Sections will also review the viral and protozoan contaminants 
of greatest concern to transfusion medicine, how they are introduced into products, 
and the techniques in place to detect them and prevent their transmission to the 
recipient. 
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Table 1.1: Quality controlled characteristics of blood 
products- 
(Adapted from Contreras, 1998) 
Mandatory screening 
(WB) 1% Screening (blood products) 
ABO grouping 
Rh D typing 
RCCs: volume, residual WBCs, residual 
platelets and packed cell volume 
PCs: volume, platelet count, residual 
WBCs, residual RBCs and pH 
FFP: volume, factor VIIIC content 
Cryoprecipitate: volume, factor VII content 
RhC and E typing 
Antibodies to red cell 
antigens 
Haemoglobin 
HLA typing (when 
required) 
1.4.1 Viruses 
Viruses are obligate intracellular parasites that are responsible for numerous 
life-threatening diseases. Blood-borne viruses such as hepatitis C virus (HCV) can 
be highly infectious, with high mortality rates. Hence, screening for virus infection 
constitutes the most extensive branch of testing performed on blood products. 
Detection at the ARCBS is achieved by two methods: serological-based assays, such 
as the currently used chemiluminescence immunoassay (ChLIA — Abbott PRISM), 
and nucleic acid amplification test (NAT — Chiron Gen-Probe). Both assay systems 
are specifically designed for high-throughput screening. Table 1.2 shows the viruses 
screened and the methods by which they are detected at the ARCBS. 
Serological assays for viral antigen/antibody detection have been in routine 
use for many years. The automated Abbott PRISM ChLIA-based assay system is a 
more recent development. The virus-serological assays are sensitive and specific, 
but are dependent upon the seroconversion status of the individual. That is, donors 
that are infected and producing antibodies in response. If the donor has not yet 
seroconverted (as happens during the 'window period'), a false-negative result may 
be obtained. HIV infection produces a 22 day window period, while HCV may have 
a window period of up to 70 days (2, 59, 101, 131). A further limitation is that 
sensitivity and specificity of the test can be compromised, such as when samples are 
frozen prior to testing. 
To overcome these issues, the ARCBS also employs the NAT, which 
currently detects HIV and HCV. Detection of other viruses by the automated Chiron 
NAT system is currently being developed. 
With this system, the viral nucleic acid (if present) is amplified and detected 
by hybridisation protection assay utilising a chemiluminescence-coupled 
complementary RNA probe that is quantitated (in relative light units) in a 
luminometer (8). The NAT technique reduces the window period by up to 14 days 
for HIV and by up to 30 days for HCV (2, 93). While the NAT technique is not fail-
safe, it offers increased assurance of blood product safety. 
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Table 1.2: Mandatory viral screening tests currently applied 













HIV-1 and 2 
HBV 
HCV 






Yes (as required) 
1.4.2 Parasites 
In Australia, transmission of parasites by blood donation is rare, as any 
individual who may have been exposed to parasitic infections by clinical or travel 
avenues within the preceding 6 months, will be excluded at the pre-donation 
questionnaire stage (56). 
Malaria is the most common parasitic disease of concern. It generally occurs 
between the latitudes 45 degrees north and 40 degrees south of the equator, although 
cases have been reported elsewhere. The causative agents of malaria are 
Plasmodium falciparum, P. vivax, P. ovale and P. malariae. P. falciparum is the 
most dangerous of these human parasites as it can infect the brain (75). Natural 
transmission occurs by the Anopheles mosquito, followed by a 12 day to 10 month 
incubation period. The malarial parasite is restricted to within RBCs, which may 
then contaminate blood products containing either residual (e.g. PCs) or many (e.g. 
RCCs) RBCs. Invasion and multiplication within the RBC eventually leads to the 
destruction of the host cell, the release of new progeny, and anaemia (95). Clinical 
symptoms of infection reappear with each round of parasitic multiplication. 
Travellers who have been in an area considered endemic for malaria are excluded 
from donating for one year following travel, whilst immigrants from such areas are 
precluded for a period of 3 years (56). Each of the above parasites can survive 
storage at 4°C for more than a week. 
1.4.3 Syphilis (Treponema pallidum) 
The bacterial spirochete, T. pallidum is normally transmitted sexually, but can 
also be transmitted congenitally and by fresh blood and PCs. The sexually-
transmitted infection progresses through three stages: the primary, characterised by a 
lesion at the site of infection known as a `chancre'; the secondary, whereby the 
bacteria become blood-borne; and the tertiary, where the bacteria leave the blood 
stream and invade the heart, musculoskeletal system and central nervous system. 
Symptoms such as a rash and fever may be absent from the infected individual at the 
primary and secondary phases, and the symptoms of tertiary syphilis including heart 
damage, neurological symptoms and skin lesions develop over a period of years or 
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decades. Treatment requires antibiotics and is most successful if the disease is 
diagnosed at an early stage of infection. Screening for T. pallidum is by a serological 
assay which detects anti-cardiolipin antibodies. Cardiolipin is a lipid normally found 
in mammalian mitochondrial membranes and hence, it is not normally in contact 
with the immune system. The lesions associated with syphilis presumably are 
responsible for the release of cardiolipin, although viral infection, autoimmune 
disease and some malignancies can generate the same lipid release and result in 
false-positive detection (58, 171). Also, in early primary syphilis at the height of 
infectivity, screening tests may be negative. Although it has been reported that 
T. pallidum is inactivated by refrigeration for >72 hours (53), mandatory 
precautionary screening occurs at the ARCBS. 
1.4.4 General bacterial contaminant screening 
In Australia, the approach used to detect bacterial contaminants in samples of 
blood products utilises automated culture, such as BacTAlert (Organin Teknika, now 
Bio Merieux) whereby positive samples are identified by increasing levels of CO2 
within the cultures bottles as the bacteria proliferate. As this process is dependent on 
the rate of proliferation of the bacteria, this method may take up to seven days for a 
positive result to be recorded. Automated culture may also be subject to false-
positive results (i.e. reculture is negative following BacTAlert positive detection). In 
countries such as Belgium, it has been reported that more than a third of initially 
positive automated cultures are negative upon reculture (183). Some countries also 
employ a Gram or acridine orange stain for all blood products prior to transfusion. 
However, this is not the case in Australia as these tests are not considered sufficiently 
sensitive for accurate detection of bacterial contaminants at lower concentrations 
(discussed in more detail in Section 1.7.3) (86). 
Following the positive identification of a contaminated product, the 
bacterium is identified by a commercial API kit (Bio Merieux). This consists of a 
strip of colour reaction tests investigating the fermentative abilities of different 
bacteria. Cultures are grown on a range of semi-solid media (chocolate, MacConkey 
and blood agar) under aerobic and anaerobic conditions for 24 to 48 hours and are 
Gram-stained. The results of these preliminary tests and the identified morphology 
of the bacterium (rod, coccus) enable selection of an appropriate API test for the 
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suspected organism. The API test results are then compared with the standardised 
test results of various organisms. 
1.4.4.1 	Common bacterial contaminants 
The bacterial contaminants commonly isolated from blood components in the 
USA and Australia are shown in Figures 1.2 and 1.3. There appears to be a 
considerable difference between the organisms isolated in each country (e.g., more 
skin commensals are evident from the Australian data). However, it may be due to 
the variation in donor populations between these countries, as until recently, most 
blood banks in the USA were paid operations, whilst the ARCBS donors are 
voluntary. It is widely believed that voluntary donation systems attract 'healthier', 
(hence lower risk) donors. Also, the Australian data for the bacterial species 
identified in blood products have been obtained by the screening of 1% of all blood 
products manufactured, whilst the results from the USA were obtained from culture 
of the remaining product after a reported episode of suspected TTBS (116, 175). It 
could, therefore, be concluded that the Australian data provides a profile of the 
complete spectrum of bacteria that contaminate and persist in blood products, while 
the data from the USA represents the organisms most frequently causing sepsis 
following inadvertent transfusion of bacteria-contaminated products. 
This suggestion is supported by the similarity of microorganisms obtained from 
prospective surveys conducted elsewhere, to those found by the Australia survey (14, 
22, 25, 65, 119, 128, 174, 225). The combined data give a diverse array of more than 
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Figure 1.2: Bacteria in red cell concentrates 
a) Common contaminants found in 1% of RCCs by routine 
automated culture. 
b) Species indicated in RCC transfusion-transmitted bacterial sepsis. 




































Figure 1.3: Bacteria in platelet concentrates 
a) Common contaminants found in 1% of PCs by routine 
automated culture. 
b) Species indicated in PC transfusion-transmitted bacterial sepsis. 
(data from Kuehnert, 2001; Roth, 2001; and Baleriola-Lucas, 2001) 
1.5 Bacterial entry and establishment in blood products 
The contamination of blood products by bacteria can occur by several 
pathways. Bacteria are usually introduced at low numbers (5 to 10 CFU/niL) into the 
WB or blood products (7, 24, 57, 76, 78, 201). However, long periods of storage 
under conditions that allow bacterial proliferation, provide opportunity for the 
contaminants to multiply to clinically significant numbers (>10 5 CFU/mL) (226) and 
pose a risk to recipients. However, entry does not guarantee the survival or 
proliferation of the organism. These issues are addressed below. 
1.5.1 Routes of contaminant entry 
Contamination occurs most frequently through incomplete antisepsis of the 
venepuncture site, but may also occur following donor bacteraemia, or processing 
with non-sterile equipment. 
1.5.1.1 	Incomplete skin disinfection 
There is considerable evidence that suggests incomplete disinfection at the 
antecubital fossa is a common occurrence. The most frequently implicated 
microorganisms in TTBS are skin flora such as Staphylococcus epidermidis 
(hereafter referred to as S. epidermidis) and Staphylococcus aureus (S. aureus). 
Moreover, Goldman (80) showed that antiseptic skin preparations are not always 
effective. In that study, volunteers were subjected to disinfection of the antecubital 
site with a range of antiseptics on discrete occasions. Quantitation of the 
contaminants post-disinfection was by contact plate count, and each contaminant was 
identified. The most effective method appeared to begin with a 70% isopropanol 
scrub followed by a 2% tincture of iodine scrub. However, the findings of this study 
are limited by the fact that no contact plate counts of the antecubital fossa bacterial 
load pre-disinfection were taken for comparison with the post-disinfection count. An 
earlier study reported a 2% chlorhexidine preparation was more effective than either 
a 10% povidone-iodine or 70% alcohol swab in skin antisepsis, and also provided a 
residual antibacterial activity for several hours after application (125). The ARCBS 
currently utilises a simple 70% isopropanol scrub for disinfection, but in light of the 
above findings, this is under review. 
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A further complexity to the skin antisepsis problem as reported by Anderson 
(5), was that despite careful iodophor disinfection, 'dimpling' of the antecubital fossa 
in long-term donors led to a culture of coagulase-negative staphylococci in repeat 
blood samples taken from the area. Blood taken from non-dimpled sites was culture-
negative. This may be due to a small core of skin entering the collection bag at the 
time of donation through the venepuncture needle, as WB contamination persisted 
despite the fact that post-disinfection surface sampling of the antecubital site yielded 
no bacterial growth (77, 79). This suggests that despite an effective and complete 
surface disinfection of the venepuncture site, surface disinfection alone is insufficient 
to prevent the contamination of WB donations. The ARCBS has attempted to reduce 
the possibility of contamination in this way by avoiding the venepuncture of dimpled 
skin in all donors, although there has been no investigation into the efficacy of this 
practice in a large-scale operation such as a blood bank. 
1.5.1.2 Donor bacteraemia 
Although most people who are bacteraemic are also symptomatic, episodic 
bacteraemia may occur in people who appear well (79). The lack of visible 
symptoms in a healthy individual may be due to a number of reasons, such as a low 
concentration of microorganisms in the blood during the incubation or recovery 
period of infection, or during a long-term asymptomatic carriage of the bacterium 
(79). When combined, these present particular difficulty in assessing the health of a 
potential donor, and are likely to be responsible for a substantial number of all 
bacteria-contaminated products. The organisms most commonly implicated in the 
contamination of blood products via this route are Y. enterocolitica or Salmonella 
enterica. which can invade the intestinal mucosa and become blood-borne (57, 90). 
Epidemiological evidence largely supports this idea, as one third of WB 
donors implicated in Y enterocolitica transmission via red cells products, have been 
reported to have experienced gastrointestinal illness (prior to, during or soon after 
donating blood) which is an established hallmark of Y. enterocolitica infection. 
T. pallidum is also a blood-borne pathogen that can mediate TTBS, although this 
rarely occurs. Contaminants acquired via this route have also been detected in other 
blood components such as PCs and HT, and caused infection following transfusion 
of these products. A notable, yet unusual outbreak of Salmonella Cholerae-suis 
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followed the apheresis extraction of plasma from an asymptomatic donor. It was 
later inferred that the patient unknowingly had osteomyelitis of the tibia with low-
grade chronic bacteraemia (169). Dental procedures and even toothbrushing have 
occasionally been implicated as the source of organisms such as S. aureus, Serratia 
liquefaciens (hereafter referred to as Serr. liquefaciens) and viridans group 
streptococci (19, 31, 79, 147, 154). The bacteraemic phenomenon, however, appears 
transient when donor infection occurs via this route, and potential blood donors who 
have undergone any dental work are only deferred from donating blood on the same 
day to prevent possible transmission of infection as a result of such procedures (82, 
147, 200). 
1.5.1.3 	Non-sterile equipment 
Contaminated equipment has been linked to several episodes of TTBS 
although this route of contamination is now rare since the development of closed 
blood collection systems. The most recent report of such contamination involved a 
simultaneous outbreak of Serr. marcescens in Denmark and Sweden. This was 
subsequently traced to a batch of contaminated single-use blood collection containers 
from which a ribotype analysis revealed that the organism from the contaminated 
products matched an isolate obtained at the manufacturing plant (91, 99). 
1.5.1.4 Contamination during processing 
AuBuchon (10), simply yet elegantly demonstrated that the use of an aseptic 
blood-bag side tube sealing device does not necessarily guarantee a sterile product. 
When 244 seals made by the device were challenged externally to the seal with 
bacteria, pack sampling resulted in two being positive for contamination, indicating 
bacteria could enter through what was considered to be an aseptically produced seal. 
It was subsequently recommended that all welds be visually inspected when 
produced, as both in this case were found to be incomplete. If contaminated, 37 °C 
waterbaths provide ideal conditions for the growth of many bacterial species, and it 
is reported that up to 54% of all episodes of product contamination following 
thawing of 14141' have resulted from the introduction of bacteria from a waterbath to 
the product through microscopic cracks in the container (212). This risk, can 
however, be avoided by the use of sterile container `overwraps' in conjunction with 
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regular disinfection of the waterbath, or by use of the alternative of microwave 
thawing of frozen products (44, 212). 
1.5.2 Factors influencing bacterial establishment in blood products 
As mentioned previously, the introduction of bacteria into WB or blood 
products does not guarantee their survival or proliferation. Some bacteria have 
fastidious nutritional or conditional growth requirements which may not be met by 
the product, or it may be out-competed for the limited resources by a more quickly 
adaptive and opportunistic co-contaminant. Moreover, as an intrinsic part of the 
complex human immune system, blood is also capable of generating a natural 
antimicrobial activity that may reduce or eliminate the microorganism prior its 
establishment (32). 
1.5.2.1 	Blood component characteristics and storage 
The storage temperature and properties of each blood product have been 
chosen to optimise the preservation of the products during storage. However, the 
temperatures used also act to restrict the range of contaminants to organisms capable 
of inhabiting and multiplying in those specific niche environments. This will now be 
explored further for red cell and platelet products. til-P and other products that are 
stored in the frozen state will not be considered further as they have only on rare 
occasions been implicated in TTBS. 
The storage of RCCs under refrigeration (4 ± 2°C), whilst allowing the 
survival and persistence of many species of bacteria, restricts proliferation to species 
which are psychrophilic. Most bacteria studied previously in PRP products, which 
are able to proliferate under these conditions, experience a growth lag period of at 
least 7 days in RCCs, followed by a gradual exponential increase in concentration 
over the next 14 days (7, 73). The psychrophilic pseudomonads aptly fill these 
criteria. However, there are some organisms, not strictly considered psychrophilic 
that successfully proliferate in RCCs. Y. enterocolitica is not considered 
psychrophilic, yet in the USA it is responsible for more than 50% of all contaminated 
red cell products tested and is able to proliferate at 4 °C (34). Growth of this 
organism may be enhanced by the long storage period of RCCs, and the plentiful 
availability of iron. Bacterial species including S. aureus and S. epidermidis which 
22 
are also not considered psychrophilic have also been reportedly linked to episodes of 
RCC patient sepsis, and this may be due to the production of bacterial superantigens 
or other toxins (116, 164, 216, 217). Further information about the behaviour of 
these bacteria in stored blood products would therefore be highly useful in explaining 
the mechanisms of patient disease in these cases. 
A larger and more diverse range of contaminants have been found in PCs 
(especially pooled buffy coat PCs) than RCCs, due to their storage at 22 ± 2°C with 
constant agitation (Section 1.2.4.3). They are generally considered as the product of 
greatest infectious concern to transfusion medicine (23). Most organisms isolated 
from PCs are skin saprophytes. They include S. epidermidis and Propionibacterium 
acnes (hereafter referred to as Pr. acnes), or perpetrators of gastroenteritis such as 
Salmonella enterica, Bacillus spp., or E. coli. Notably, many of these organisms are 
aerobic, thriving in the high oxygen tension of PCs. Anaerobes also multiply freely 
in PCs, provided they are not obligate anaerobes. Typically, PC contaminants spiked 
into PRP PCs exhibit a lag phase of 24 hours, followed by an exponential growth of 
up to approximately 10 8 CFU/mL (160, 201). The concern over the contamination of 
PCs with bacteria, limits storage to 5 days although viability of the product can be 
maintained for 7 days (Section 1.2.4.3). Although this practice reduces the risk of 
transfusion of products containing significant numbers of bacteria, it leads to 
significant challenges for efficient product inventory management. 
1.5.3 Prevention of contamination 
Despite the apparent ease with which bacteria can enter blood products, there 
are a number of procedures that may assist in the prevention of this. 
1.5.3.1 Blood diversion 
Several studies have shown that the first 10 to 15 mL of WB taken, are more 
likely to contain bacteria than further samples (36, 147). Bruneau (36) recorded a 
72% reduction in the number of contaminated products if this precaution was taken, 
confirming the finding that contamination occurs most frequently at the time of 
collection (189). However, 100% sterility of products remains unobtainable, and this 
procedure is not in use at the ARCBS. 
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1.5.3.2 Whole blood holding period 
Freshly-drawn blood contains WBCs which phagocytose bacteria, and plasma 
which contains complement proteins to suppress bacterial proliferation (6). This has 
been exploited by the ARCBS, where an overnight WB holding period following 
collection is in place. Evidence from Hogman (100) also supports that WBC have a 
bactericidal effect upon a range of organisms including S. epidermidis, S. aureus, 
Pseudomonas aeruginosa (hereafter referred to as P. aeruginosa) and 
Propionibacterium spp. following inoculation into WB of between 1 to 100 
CFU/mL. Within 5 hours, all organisms tested were reduced by at least 1 to 2 logs in 
WB containing WBCs, in comparison to WBC-depleted WB. It has not, however, 
been investigated whether this phenomenon is dependent upon the WBC count. That 
is, whether a higher concentration of WBC achieves greater bactericidal effect than a 
lower concentration (although this would be a logical hypothesis). There is also 
some debate into the legitimacy of the flogman (99) study as the bacterial species 
were cultured in vitro and were not grown in blood. As many virulence factors are 
located extrachromosomally on plasmids that may be 'lost' when bacteria are 
cultured, this may render the bacteria particularly vulnerable to phagocytic killing by 
WBC (such as happens with Y. enterocolitica when kept at 22°C) (98, 148). 
Therefore repeated studies should be conducted by selectively culturing the bacteria 
to retain their virulence plasmids, to determine if the results observed were real. 
Furthermore, some investigators have suggested that WBCs should be filtered from 
the products following the holding period, as evidence suggests that some bacteria 
(such as Y. enterocolitica) may remain viable following phagocytosis, and escape 
upon the death of the phagocyte (66, 100). 
Should bacteria be able to enter, establish and proliferate, spoilage of these 
blood products is inevitable. More serious are the risks posed to recipients of such 
contaminated products. 
1.6 	Transfusion-transmitted bacterial infections 
The symptoms of bacterial septic reactions (listed in Table 1.3) are relatively 
non-specific, making recognition a complex problem, particularly with the variety of 
clinical sequelae that may occur post-transfusion. There is some debate as to 
whether particular clinical manifestations can be used as a direct guide to the 
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diagnosis of TTBI, as most symptoms are identical to those of other acute haemolytic 
transfusion reactions, and further may lead to misdiagnosis (86). Symptoms of TTBI 
usually present within the first few hours, with more than 70% of TTBI cases first 
presenting symptoms during the transfusion (86). Recipients have reported a violent 
chill during or immediately following the application of the contaminated product. 
This may be accompanied by an increase in polymorphonuclear neutrophils 
(PMNs) in the blood, fever, tachycardia, hypotension, nausea, vomiting and 
circulatory collapse in the case of progressed septic shock (28, 141, 142). The 
outcome of septic shock varies depending on the recipient's immune system, its early 
recognition, the immediate discontinuation of the transfusion, and the application of 
appropriate antibiotics and additional supportive measures (6, 79). Atypical 
symptomatic TTBI cases are rare, but it is important to attempt to identify the most 
common sequelae, as if recognised and treated early, more than 80% of infected 
individuals survive. More than 70% die if the infection progresses to septic shock. 
1.6.1 Bacteraemia 
The term `bacteraemia' refers simply to the presence of bacteria in the blood, 
which although a clear indication of infection, may not manifest in visible symptoms 
(6). This is especially true in healthy individuals where contaminating organisms are 
quickly removed by immune mechanisms such as phagocytic cells in the blood, or 
the Kuppfer cells in the liver (6). Unlike healthy donors, the state of bacteraemia in 
immunocompromised transfusion recipients can quickly lead to established disease 
such as sepsis. 
The bacteraemic condition as a precursor to sepsis is exceptionally 
concerning as all patients transfused with bacterially-contaminated products could be 
considered bacteraemic and are hence at a high risk of sepsis, particularly as most 
recipients are immunocompromised. 
1.6.2 Sepsis, septicaemia, and septic shock 
Sepsis is a condition that results from bacteraemia, and involves the 
putrefactive destruction of tissues by disease-causing bacteria or their toxins, 
accompanied by a febrile reaction (209, 213). 
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Table 1.3: Frequency and type of transfusion-transmitted 
bacterial infection symptoms 
(Adapted from Greene, 1995) 
Frequency 




Disseminated intravascular coagulation 
Nausea 
Vomiting 
Acute respiratory failure 
























Sepsis leads to 'septicaemia', a systemic disease in which the organism continuously 
multiplies in the blood. The symptoms of sepsis are the same for both Gram-positive 
and Gram-negative organisms. Septic shock is triggered when bacterial cell wall 
components or lipopolysaccharide (LPS) are released into the blood, although the 
mechanisms for the sequelae of events remain poorly defined (151). Following 
bacterial lysis, it is thought that LPS is bound by an LPS-binding protein, which in 
turn binds the CD14 molecule on monocytes and macrophages (Fig. 1.4). The LPS-
LPS binding protein complex also has the ability to bind to surface receptors of 
epithelial cells. Following complex binding with the host cells, cytokines such as IL-
1, IL-6, IL-8, TNFa and platelet activating factor (PAF) are produced which in turn 
stimulate a range of physiological responses. Amongst other functions, IL-1 causes 
an increase in PMN numbers and stimulates prostaglandin production, causing fever. 
When injected into animal models, IL-1 can also induce shock. However, it is 
unknown what discernible further roles it plays at this stage. TNFa, IL-6, IL-8, 
PAF, prostaglandins and leukotrienes all affect blood vessels causing abnormal 
endothelial function, such as constriction or relaxation. Complement is activated, 
and component C5a causes the PMNs to stick to blood vessel walls where they may 
release lysosomal enzymes and produce extensive damage. Activation of the 
coagulation cascade produces small clots and a condition known a disseminated 
intravascular coagulation (DIC) where blood vessels are blocked and normal blood 
flow inhibited, causing a dramatic drop in blood pressure (120, 121). The drastic 
drop in blood pressure results in a lack of oxygen flow to the major organs of the 
body such as the brain, heart and lungs. The high consumption of fibrinogen and 
platelets leads to an overall deficiency of available clotting components and leads to 
haemorrhages throughout the body. Acute respiratory distress syndrome (ARDS) is 
probably caused as a result of the coagulation cascade and is characterised by 
accumulation of fluid in the lungs causing insufficient gaseous exchange which is 
often the cause of death in septic shock sufferers (9, 71, 72, 74). Death due to septic 
shock has been reported to occur as little as 50 min to as much as 17 days post-
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Figure 1.4: Schematic of LPS-induced sepsis 
(Adapted from Salyers and Whitt, 1994) 
Diagnosis and treatment of sepsis involves a peripheral blood smear which is 
examined for the absence of haemolysis. A Gram stain may provide similar 
information, although this technique is unreliable with less than 10 6 CFU/mL present 
in the sample (See also Section 1.7.3). An elevated WBC count would similarly 
suggest a tentative diagnosis of sepsis (86). Treatment must begin immediately, even 
prior to the identification of the organism responsible, with broad-spectrum 
antimicrobials of sufficient strength to counteract the most likely organisms, such as 
Y. enterocolitica and Pseudomonas spp. in RCCs and Gram-positive species in PCs 
(215). For RCC recipients, the most common treatment is an antipseudomonal 
penicillin in conjunction with co-trimoxazole to cover any possible Y. enterocolitica 
infection, while PC recipients commonly receive vancomycin and ceftazidime, 
particularly if the Gram-stain is negative (86, 214, 215, 227). It is, however, 
important to note that there have been reports of deaths following apparent recovery, 
and even when antibiotics have been applied as a prophylactic measure. 
1.6.3 Incidence of transfusion-transmitted infections 
The incidence of each microbial contaminant varies from country to country, 
depending upon the screening regime (including the donor questionnaire), the 
phlebotomy technique, and the antiseptic employed. However, in light of the data 
published by Chiu (49) and findings published since from the BaCon, SHOT and 
French haemovigilance studies, (63, 83, 116, 118, 175) indicating bacterial 
septicaemia is the most common transmitted infectious risk in transfusion medicine 
today, it is clear that the overall problem of TTBS is considerable (Table 1.4). These 
report between 10 to 72 PC and 0.2 to 5.8 RCC TTBS incidents, for every million 
transfusions conducted (35, 6, 81, 109, 132). 
However the issue of underreporting (further explored in Sections 1.6 to 
1.6.4) has led to suggestions that as many as 750 deaths per year occur as a result of 
TTBS in the USA alone (103). Unfortunately, there is a lack of equivalent 




USA: 1 in 58 000 to 149 000 
Australia: 1 in 1 339 000 
USA: 1 in 872 000 to1 in 1.7x10 6 
Australia: 1 in 3 636 000 
USA: 1 in 1.4 x10 6 to 1 in 2.4 x10 6 
Australia: 1 in 7 299 000 
USA: 1 in 350 to 1 in 2000 
Australia: Not available 
USA: 1 in 1 000 000 








Table 1.4: Estimated current risk of transfusion transmitted 
infections per unit transfused 
(from Menitove, 1996, Goodnough, 2003, Kiely, 2004, and 
Brecher, 2005) 
1.6.4 Scope of transfusion-transmitted bacterial septicaemia 
The symptoms of TTBS closely resemble other transfusion episodes, such 
non-haemolytic transfusion reactions, and hence TTBS may be misdiagnosed (132). 
Cross-matching of the isolate cultured from the recipient, blood product, and the 
donor provides a definite connection of the contaminated product to a case of TTBI. 
Unfortunately, this process can be significantly impeded. Although TTBS may be 
suspected, the organism responsible may not be cultured from either the patient or 
the product, or the product may be discarded before a culture can be made. Negative 
cultures from patients are most likely due to the prophylactic treatment of patients 
with antibiotics, as the bacteria may be non-viable (although their remnants continue 
to stimulate the patient's immune system). Moreover, as the organisms implicated in 
TTBS are frequently skin flora, they are often thought of as being insignificant when 
isolated in a clinical setting from patient blood cultures. Muder (139) reported an 
atypical case such as this, where the primary physician dismissed two repeated blood 
cultures of S. epidermidis, and remained unconvinced of the significance of this 
result until the same microorganism was cultured from a third blood sample. 
Moreover, catheters and tubing are prone to bacterial contamination and the 
formation of biofilms (6). These items and procedures may therefore be incorrectly 
implicated as the source of the causative agent of a septic reaction, rather than the 
transfusion product. Finally, the most substantial reason for the postulated 
underreporting of TTBS is attributable to antibiotics. These are frequently 
prescribed to prevent opportunistic bacterial infections in transfusion recipients as 
most of these recipients are immunocompromised (53). This practice, although 
preventing spontaneous cases of infection, may also mask episodes of TTBS. 
However, the blanket application of prophylactic antibiotics to transfusion recipients 
may not be the simple solution to the TTBI problem, as is popularly thought. There 
are three reasons for this. Firstly, as 50% of organisms implicated in sepsis are 
Gram-negative, they can subsequently acquire resistance to some antibiotics, 
especially in a hospital setting. There has also been a documented increase in the 
antibiotic resistance of Gram-positive organisms. So while antibiotic treatment may 
be considered effective today, an increase in antibiotic resistance by many common 
bacterial pathogens has left patients susceptible to acquiring untreatable infections 
(25). Vancomycin-resistant S. aureus (VRSA) were isolated from a hospital 
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environment in 2002 (161). As this group of bacteria is one of the most common 
contaminants of PCs, its entrance into the blood banking system is highly likely. 
Secondly, TTBS mortality has been recorded despite the prophylactic application of 
antibiotics (as mentioned in Section 1.6.2). Finally, other considerations such as 
antibiotic toxicity and expense must also be taken into account. 
Clearly, the problem of bacterial contamination is multifaceted and complex, 
and cannot be solved by prevention of contamination or suppressing bacterial 
growth, or monitoring for product spoilage. Moreover, it is difficult to accurately 
and quickly diagnose sepsis in a recipient (which has contributed to the 
underreporting of incidents), a situation which may rapidly lead to their death. The 
viral screening in place today reflects the serious nature and consideration of the 
viruses concerned. However bacterial contamination and transmission via blood 
products is considered with much less scrutiny although recent evidence suggests 
that the true scope and magnitude of this is much larger than the viral problem. In 
consideration of the limited bacterial screening of products and the potential risk to 
recipients, the need for additional screening methods has been raised. 
1.7 Methods available for the detection of bacterial contaminants 
The detection of bacterial contaminants in blood components is a complex 
problem, and a screening test to detect all relevant bacterial contaminants has strict 
requirements, as follows. 
1.7.1 Requirements of an 'ideal' test 
There are four basic requirements for an ideal test: 
1. Specificity: The false-positive and false-negative rates should be significantly 
lower than the estimated rate of sepsis. 
2. Sensitivity: The test should be able to detect bacteria at lower concentrations 
than the numbers needed for a septic reaction (<10 4 CFU/mL) (133). 
3. Speed: 
	
	The test must be rapid enough for timely product clearance and 
distribution. 
4. Simplicity: The results should be easy to interpret, with little or no 
instrumentation required. The test itself should be simple to 
perform, with as few steps as possible to minimise operator error. 
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In addition to these four key elements, the test should not be prohibitively 
expensive, and should be able to detect a wide range of bacteria in all blood product 
types (133, 200). The common screening methods available today will now be 
discussed and assessed as to how adequately they fulfil each of these requirements. 
Following this, more recent methodologies proposed for investigation in this thesis 
will be reviewed. 
1.7.2 Visual inspection of products 
Detection of bacterial contamination by simple visual inspection is 
particularly appealing as it requires no equipment. There is no expense and the 
technique is non-invasive (133). A number of features which are different for each 
of the main products of concern, RCCs and PCs, can be utilised to determine the 
presence of bacterial contamination. 
1.7.2.1 	Red cell concentrates 
Kim (112) noted that when RCCs were deliberately contaminated with Y. 
enterocolitica, the culture-positive main bag section of the product was darker than 
attached side tube segments which were culture-negative. The same phenomenon 
has been observed with a range of other species (110). Kim was able to demonstrate 
that haemolysis was responsible for the darkening colour, and this became apparent 
upon visual inspection with contaminating numbers of bacteria greater than of 108 
CFU/mL (110). Pickard (156) reported that trained personnel could detect spoilage 
from bacterial contamination with as few as 10 4 CFU/mL present with 97% 
accuracy, when the blood pack side tubing was considered in comparison to the main 
bag. However, the accuracy dropped to 47% when the blood pack main bag was 
considered on its own. Pickard's observations were unreliable, however, as some 
positive identifications were only able to be made when bacterial numbers peaked at 
109 CFU/mL, whilst some uncontaminated packs were identified as contaminated 
(156). The unreliability of this technique has been well documented. In the two 
years prior to 1992 in the USA, there were seven fatalities involving 
Y. enterocolitica. Of these fatalities, most were following the transfusion of RCCs 
that showed no gross evidence of contamination (7, 105, 192). Clearly this bacterial 
detection technique when used alone is unreliable and insensitive, but there are 
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additional limitations beyond these basic problems. The technique of comparing the 
blood bag with side tubing prior to transfusion can only be applied to RCCs, and 
therefore is unsuitable as the sole method of detection for bacterial contamination. It 
may, however, be used in tandem with other detection methods such as automated 
culture. 
1.7.2.2 	Platelet concentrates 
A phenomenon known as 'swirling' or 'streaming' is associated with normal 
platelet discoid morphology and is used to evaluate each PC qualitatively for 
viability (18). This is done by tapping or inverting the PC product during exposure 
to a light source, whereby normal platelets will reflect the light, whereas non-discoid 
platelets will not (133). Wagner and Robinette (203) observed that the swirling 
effect ceased to be observed at bacterial concentrations of 10 7 to 108 CFU1mL. 
Clotting, small white clumps and a light green colour were also seen in some 
instances. Further investigation revealed the cessation of the swirling effect was 
attributable to a decrease in pH produced as a result of the metabolism of the 
bacteria. However, bacterial contamination is not the only cause of the loss of 
swirling. Bertolini (18) and Wagner and Robinette (203) demonstrated 
independently that a number of other factors also contribute to the lack of swirling, 
including prolonged storage at 22 °C and lower storage temperatures. The latter 
group clearly indicated that up to 18% of PC showed no swirling effect by day 5 of 
storage at normal PC storage conditions. This would result in an unacceptably high 
level of false-positives, (even though these non-swirling PC may not be an effective 
therapeutic product if they were transfused to a recipient). 
In conclusion, the evaluation of PCs for bacterial contamination by swirling, 
clotting, or colour changes, must be considered in the same light as evaluation of 
RCCs by pack darkening. Both are relatively insensitive techniques on their own. 
Due to this, PC examination is used with other detection techniques, such as 
automated culture. 
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1.7.3 Staining: Gram and acridine orange 
Staining techniques explored in the detection of bacterial contaminants of 
blood products include Gram stain and acridine orange. Reik (165) found that at 
concentrations of 105 CFU/mL in buffy coat smears, approximately 7 
microorganisms were visible on Gram staining in a single high power field of view 
on close inspection. At 106 CFU/mL, 50 to 100 microorganisms were apparent at the 
same magnification. This variance may be attributable to the differential clumping 
ability of each individual organism, or properties of products themselves. This is 
supported by Yomotovian (225) who cites a case of a contaminated PC unit with 
more than 107 CFU/mL of P. aeruginosa that was deemed negative, a result that was 
attributed to the clumping nature of the organism. They further determined that true 
positive results with PCs were only reliable with contamination levels of 106 
CFU/mL or more, and that sensitivity prior to day 4 of storage was only 
approximately 80%. Hence, unreliability and relative insensitivity appear to be the 
greatest limiting factors in the implementation of this technique for routine screening 
for contaminants. However, as it is relatively inexpensive and quick, it is used 
overseas in some blood centres to reduce the likelihood of transfusing highly 
contaminated products (4). 
Acridine orange is used to improve the sensitivity of detection. Kim (113) 
reported that they had consistently been able to detect Y. enterocolitica in RCCs at 
concentrations between 104 to 105 CFU/mL. There is some debate as to whether this 
sensitivity applies to all organisms and all products. Chongokolwatana (51) reported 
a 100% detection success rate only with more than 106 CFU/mL, and an 83% 
detection success rate with bacterial concentrations of 105 to 106 CFU/mL. 
Therefore, acridine orange appears to suffer from similar drawbacks to the Gram 
stain in terms of sensitivity. Additionally, it requires a fluorescence microscope for 
visualisation of the bacteria. 
In conclusion, this technique has its place as an interim pre-transfusion 
detector of contaminants. However, as there appears to be no conclusive evidence 
supporting the greater sensitivity of acridine orange over the Gram stain, and there is 
the requirement of additional detection equipment for the former, it may be more 
appropriate and cheaper to utilise the Gram-stain for routine screening. 
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1.7.4 Limulus amoebocyte lysate assay 
The Limulus amoebocyte lysate (LAL) assay has been extensively 
described in the literature and detects bacterial endotoxin (7, 112). Arduino (7) 
detected endotoxin in RCCs produced by bacteria of concentrations between 10 1 to 
105 CFU/mL. However one unit of a concentration of 10 3 CFU/mL was not detected 
for reasons unknown. This test is limited to detection of endotoxin-producing Gram-
negative species and the specificity and sensitivity of the test appear unreliable. 
Hence, it is unsuitable as a stand-alone method for pre-transfusion product testing (7, 
193). As for the previously described techniques (Sections 1.7.1 to 1.7.3), it may be 
used in conjunction with other interim screening measures as an indicator of bacterial 
contamination, rather than as an absolute screening method. 
1.7.5 Short-term culture 
Short-term culture is conducted by sampling PCs at day 3 of storage, and 
detection of bacterial growth is facilitated by an automated culture machine (120). 
Blachman (27) found that of 16 290 PCs tested the day after manufacture, only 1 
positive PC was detected, but by the third day another 4 PCs were positive. A more 
recent study sought to expand these original experiments and determine whether 
sampling could be conducted at 24 or 48 hours post-inoculation, and how long a 
positive detection would take after these time-point samplings. Wagner and 
Robinette (202) found with S. epidermidis (0.1 CFU/mL inoculum) 24 hour post-
inoculation samples, that these took an average of 24 to 37 hours to become positive 
by BacTAlert. If sampling occurred 48 hours post-inoculation, the system required 
11 to 17 hours for detection. Therefore, it would still take up to 3 days to make a 
positive detection, which would allow for substantially less time for PCs to be 
transfused, if they had to be cleared by short-term culture. In addition to the slow 
speed at which automated culture operates, the false-positive rate can vary 
considerably (Section. 1.4.4). Although more rapid, short-term culture suffers from 
many of the drawbacks of conventional culture and is generally not considered 
practical for application as a screening measure for all products. However, despite 
these limitations, the USA, Belgium, the Netherlands, and most blood centres in 
Sweden, Norway and Denmark have introduced mandatory short-term culture of PCs 
to extend the shelf life of culture-negative PCs to 7 days (3). 
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Clearly, the development of the next generation of bacterial screening assays 
is warranted, utilising more sophisticated techniques than those in place today. The 
following section will attempt to define the targets most likely to be of use in a 
detection method for bacterial contaminants, and any potential limitations they may 
present. 
1.8 Detection methods to be investigated in this study 
Detection of bacterial contaminants at the nucleic acid level has been pursued 
with particular vigour since the successful development and introduction of HIV and 
HCV NAT tests. The detection of the bacterial nucleic acid has been directed along 
two major avenues. That being species-specific targeting using discrete genetic 
elements or unique regions of the bacterial ribosomal RNA (rRNA) gene, or 
targeting sequence common to multiple bacterial species, such as conserved regions 
of the rRNA gene. 
1.8.1 Bacterial 16S ribosomal genes 
Until relatively recently, the identification of microorganisms was based 
solely on culture, biochemical and serological tests. However, increasingly it was 
being found that many species could not be successfully cultured or classified based 
on these properties alone. 16S ribosomal genes are found in all bacteria, and these 
contain conserved and variable regions (Fig 1.5) (221). In the variable regions, slow 
evolution over time leads to mutations which give rise to new signature sequences, 
which can be used to identify novel bacterial species or subsets, without the need for 
culture (166-168, 220). The conserved regions are consistent in all bacterial species, 
due to structural constraints needed for the rRNA molecule to function. By using 
both conserved and variable regions, it has been possible to design broad-range and 
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Figure 1.5: Schematic diagram of the bacterial 16S rRNA gene 
1.8.2 Polymerase chain reaction (PCR) 
Feng (70) was first to demonstrate the application of the polymerase chain 
reaction (PCR) to Y. enterocolitica in WB. Amplification of the correct 
Y. enterocolitica sequence was confirmed by Southern hybridisation, and PCR 
sensitivity was estimated at 5 x103 CFU/mL. Although the sensitivity and simplicity 
of the PCR tests satisfy the requirements of the 'ideal test', (see Section 1.7.1) the 
approach used by this group enabled amplification of just one species out of a large 
spectrum of bacteria that contaminate blood products. Of more practical use, generic 
16S PCR gives the ability to detect all bacteria using primers targeted at conserved 
sequences. It has been successfully used to detect bacteria in clinical (60, 124, 188, 
210, 219) and environmental samples (87),•and may therefore provide a means for 
detecting the diverse array of bacteria found in blood products. 
There are several issues with the PCR detection of bacteria in blood products. 
The detection takes approximately 6 hours, which means it cannot be used 
immediately prior to transfusion although it may be applied at the start of each day 
during periods of low demand. Confirmation of PCR product sequence identity by 
Southern dot blotting or sequencing, can take at least another 24 to 48 hours. 
Moreover, contamination of the PCR reaction ingredients by ubiquitous 
environmental bacterial DNA, leave the test vulnerable to false-positive reactions. 
Blood products have also been found to contain proteins that interfere with the PCR 
sensitivity and hence this problem must also be overcome (1, 62, 152, 218). 
Furthermore, if universal 16S sequences are targeted, it will be impossible to identify 
if one or more bacterial species is present. The cost of PCR detection is also 
relatively expensive compared to other detection techniques, and operator 
proficiency is required for reliable performance of the test. 
1.8.3 Real-time polymerase chain reaction (real-time PCR) 
Real-time PCR is increasingly being used in preference to standard PCR as a 
diagnostic tool. While similar in theory to standard PCR, real-time PCR incorporates 
the use of generic or specific fluorescent probes within the mastermix, which 
eliminate the need for electrophoresis and staining. The primers target shorter 
sequences (usually about 150 bp) than those generally used for standard PCR, as this 
increases the speed at which the assay can be performed. Amplification and positive 
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detection can be completed in as little as 30 inin. As the reaction progresses, 
fluorescent markers are incorporated into the double-stranded amplicon, and the 
fluorescent signal (detected by laser) increases as the amount of product increases. 
Two kinds of reporters are used. SYBR green is most common, and is a generic 
method of quantifying the PCR product. It non-specifically binds to the major 
groove of DNA (similar to ethidium bromide), hence the more product, the greater 
the fluorescence, although this method cannot confirm the identity of the PCR 
product. A surrogate method termed a 'melt profile' has been developed to solve this 
problem. Each amplicon has a signature melt profile, based on its sequence (similar 
to the size of an amplicon as it is electrophoresed through an agarose gel). At the 
end of each real-time PCR run, the samples are gradually heated over a range of 
temperatures until the product melts and the fluorescent signal is extinguished. This 
temperature becomes the signature for the amplicon, and subsequent real-time PCRs 
can be judged positive (or negative) on the basis of this melt profile. Fluorescently-
labelled oligonucleotide probes can also be used, and these specifically bind to 
discrete genetic sequences within the amplicon. These can simultaneously confirm 
the identity of the amplicon as the reaction progresses. Applications using real-time 
PCR as a diagnostic assay for infectious diseases have been recently published, and 
have shown encouraging results (89, 153, 187). However, the small size of the 	
U- 
targets and the ubiquitous nature of bacterial DNA in the environment and PCR M 
reagents may result in this technique being vulnerable to false-positive results if 
applied using generic 16S sequences. The cost of real-time PCR (particularly with 
the fluorogenic probes) is significantly greater than the cost of standard PCR. 
However, as the use of real-time PCR increases, costs are likely to be greatly 
reduced. 
1.8.4 Polymerase chain reaction-enzyme linked immunoassay (PCR-ELISA) 
A molecular-based ELISA was developed as an adjunct to the PCR process, 
by which amplicons could be identified using highly specific, biotinylated capture 
probes. In this procedure, DIG-labelled PCR product samples are hybridised to 
biotinylated probes, which in turn bind to streptavidin coated 96-well microtitre 
trays. A horse radish peroxidase (HRP) conjugated anti-DIG antibody is added to 
each well, and binds to the DIG-labelled samples. A substrate is added and is 
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cleaved in the presence of the HRP, leading to colour production, which can be 
measured by spectrophotometer. An advantage of this method is that it may be fully 
automated, utilising existing infrastructure available at the ARCBS. Furthermore, it 
is rapid enough that testing may be carried out centrally at the ARCBS upon receipt 
of a bulk product order, and the test-negative products may be released for use the 
same afternoon. Also, the overall complexity of the assay is no greater than a 
standard ELISA (such as the ChLIA (Section 1.4.1) which is currently used at the 
ARCBS). 
This method has been successfully used in a range of applications, including 
the detection of viral pathogens (such as human papillomaviruses and parvovirus 
B19) (158, 228), the identification of overexpressed T cell receptor genes in blood 
and tissue biopsies (198), and in identifying a range of bacteria such as 
Mycobacterium tuberculosis (30), Listeria monocytogenes (184) and E. coli (61) in 
food and clinical samples. Using a pre-enrichment step, these tests have been found 
to have a sensitive and specific detection limit of 1 to 5 CFU per 25 g of food or 10 2 
CFU/naL of milk. However, all instances using PCR-ELISA to detect bacteria have 
utilised amplicons generated from specific gene targets. A universal 16S PCR, 
followed by probing of unique sequences within this region, would enable the 
detection of a range of bacteria using a single protocol. It is this approach that will 
be explored in this thesis 
1.8.5 Southern dot blot 
Southern dot blotting is a technique by which unknown sequences can 
identified through hybridisation with a probe of a known sequence. It can be 
performed in two orientations: with the DIG-labelled probe of known sequence in 
solution, and the unidentified sample bound to a membrane (standard orientation), or 
whereby the DIG-labelled sample is in solution, with the probes of known sequences 
bound to the membrane. Each has a unique advantage over the other. The standard 
orientation allows for many samples to be examined with a single probe, whilst 
reverse-probing allows a single sample to be tested against many probes 
simultaneously (similar to the PCR-ELISA approach). This procedure may be fully 
automated and conducted at a central testing point, which added to its appeal as a 
potential detection method. Our aim in this study was to use small oligoprobes to 
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target and identify small sequence differences between our bacterial 16S PCR 
products, in order to identify the bacterium responsible. 
1.9 Summary and objectives of the project 
The problem of bacterial contamination of blood products is a long-standing 
one. Yet it has only been in recent times (and with the success of the viral screening 
programs) that the problem of transfusion-transmitted bacterial sepsis (TTBS) has 
come into greater focus. In Australia, the incidence of TTBS is poorly defined. 
Elsewhere it is underreported, but is known to cause significant morbidity and 
mortality in the hospital setting. The methods in place today for detection of bacteria 
in blood products rely on culture-based methods, which are slow, labour intensive, 
susceptible to false results, and furthermore are only performed after the expiry of 
the blood product. This method is impractical for routine screening of all blood 
products and consequently, just 1% of each kind of blood product produced is 
screened for bacteria in Australia. 
This study will define the scope and nature of the bacterial contamination 
problem in Australia, and seek a possible solution for practical screening of blood 
products. The major aims of this project are as follows. 
1. To further identify those microorganisms most likely to be a problem in 
product spoilage and TTBS by comparing the growth characteristics of these 
bacteria in buffy coat blood products. 
2. To establish and develop a detection method that can be applied to blood and 
blood products and evaluate its use in the detection of bacterial contamination 
in such products. 
3. To evaluate the efficacy of this method on 'real' samples with bacteria grown 
in PCs and RCCs from the growth kinetic experiments, as compared with 
spiked product samples. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 	Introduction 
This chapter describes the materials and experimental techniques used to 
study the growth kinetics of bacterial contaminants in blood products (Chapter 3), the 
extraction of bacterial DNA from blood products (Chapter 4), and the detection of 
bacterial contaminants by molecular methods (Chapters 4 and 5). Methods that are 
not specifically described were performed as detailed in Current Protocols of 
Molecular Biology (11), or as stated by Sambrook (179). 
2.2 Materials 
Materials and equipment used during the course of this work were obtained 
from the companies listed in Table 2.1. 
2.2.1 Chemicals 
Analytical grade chemicals were used without further purification. Solutions 
were routinely prepared with deionised distilled water (ddH20) and sterilised by 
autoclaving at 121 °C for 20 min or passage through a 0.22 gm pore size filter 
(Millipore). 
2.2.2 Bacteriological media and culture conditions 
The manufacturers of the bacteriological media used in this study are 
presented in Table 2.1. Bacterial culture media were prepared as per the 
manufacturers' instructions, with the addition of 1.5% (wt/vol) agar (Oxoid) to 
broths when solid media were required. Sterile ddH20 was used to make all media, 
which were prepared as follows: (i) Trypticase broth: 3.0% (wt/vol) Tryptone soya 
(Oxoid) (160); (ii) Brain heart infusion (BHI): 3.7% (wt/vol) Brain-heart infusion 
(Oxoid); Horse blood agar (HBA) plates (containing 5% (vol/vol) washed horse 
erythrocytes) were purchased from Taslab Services (Launceston) and the University 
of Melbourne Media Department (Parkville). 
All bacteria were routinely cultured at 37 °C in BHI or trypticase broth with 
shaking (Y. enterocolitica and P. fluorescens were grown at 30°C). 
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Table 2.1: Suppliers of materials and equipment used in this study 
Company 	 City/State 	Country 
Amersham 	 Little Chalfont, Buckinghamshire 	United Kingdom 
Applied Biosystems 	 Foster City, CA 	 USA 
ARCBS 	 Hobart, TAS and Melbourne, VIC Australia 
Baxter Fenwal 	 Deerfield, IL 	 USA 
Baxter Fenwal La Chatre France 
BDH 	 Dorset 	 United Kingdom 
Becton Dickinson 	 Meylan Cedex 	 France 
Bio Merieux 	 St Louis, MO USA 
BioRad 	 Hercules, CA 	 USA 
Briemar Nominees 	 Kooweerup, VIC Australia 
Corbett Research Sydney, NSW 	 Australia 
CSL Ltd 	 Parkville, VIC Australia 
Difco Laboratories 	 Detroit, MI 	 USA 
Eastman Kodak Co. Rochester, NY 	 USA 
Geneworks Pty Ltd 	 Adelaide, SA Australia 
ICN Biomedicals Seven Hills, NSW 	 Australia 
Invitrogen 	 Carlsbad, CA 	 USA 
Microsoft Redmond, WA USA 
Millipore 	 Bedford, MA 	 USA 
New England Biolabs 	 Beverly, MA USA 
Nunc 	 Roskilde 	 Denmark 
Oxoid Basingstoke, Hampshire 	United Kingdom 
Pharmacia 	 Madison, WI 	 USA 
Proligo Boulder, CO USA 
Promega 	 Madison, WI 	 USA 
Qbiogene BI0101 	 Carlsbad, CA USA 
Qiagen 	 Hi!den 	 Germany 
Ratek Instruments 	 Boronia, VIC 	 Australia 
Roche Applied Science 	Basel 	 Switzerland 
Sarstedt 	 Adelaide, SA 	 Australia 
Sigma Chemical Co. 	 St. Louis, MO USA 
Spectronics Corporation Westbury, NY 	 USA 
Terumo 	 Tokyo 	 Japan 
Themo Savant 	 Holbrook, NY 	 USA 
World Precision Instruments 	Sarasota, FL USA 
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2.3 Bacterial strains 
The bacterial strains used in this study are listed in Table 2.2. 
2.4 Blood products 
PCs and RCCs were produced by the ARCBS using the buffy coat method 
according to the Council of Europe standard procedures (2003), as shown in Fig 1.1. 
Approximately 70% of PCs and RCCs obtained for this study were prepared from 
blood group B individuals, and about 25% were from group A individuals. In brief, 
450 mL of whole blood was collected into 'top-and-bottom' Optipacs (Baxter 
Fenwal, France) containing citrate-phosphate-dextrose anticoagulant. Following 
centrifugation, the RBCs (PL 146 bags - Baxter Fenwal, USA) and plasma were 
expressed into separate satellite bags using an automated blood component separator 
(Optipress, Baxter, USA) leaving the platelet-rich buffy coat in the primary pack. 
2.4.1 Platelet concentrates (PCs) 
PCs were prepared by pooling five units of ABO/Rh matched buffy coats, 
and the platelet rich fraction was transferred to a PL 2410 bag (Baxter Fenwal, USA) 
and resuspended in 300 inL T-sol® platelet additive solution (Baxter Fenwal, USA). 
The final PC products contained approximately 8 x107 WBCs/unit. PCs were stored 
under standard conditions (22 ± 2°C with agitation) for 7 d. 
2.4.2 Red cell concentrates (RCCs) 
RCCs were resuspended in 100 mL Adsol solution, and contained around 10 8 
WBCs/unit. RCCs were stored under standard conditions (4 ± 2°C, static) for 42 d. 
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2.5 Spiking and sampling of blood products 
All bacteria and products used in this thesis were prepared in the following 
manner. At least two separate experiments were conducted for each bacterial species 
and product type. 
2.5.1 Preparation of cultures 
In preparation for product spiking, bacteria were harvested by centrifugation 
(3000 xg at room temperature, RT), washed twice with sterile PBS, and resuspended 
in 5 mL PBS. The number of bacteria per mL was estimated by measuring samples at 
0D570 and comparisons with standard curves, and also confirmed by plate counts. 
The bacterial suspension was diluted to provide final concentrations of 
approximately 10, 102 or 103 CFU/mL in products when spiked with 1 mL of 
suspension. Spiking doses were selected to reflect the levels of contamination that 
may be anticipated in blood products at donation (45, 206). Products were initially 
spiked with 102 CFU/mL, and the experiment repeated with a higher (10 3 CFU/mL) 
or lower (10 CFUnnL) number of bacteria, depending on whether proliferation was 
observed with the first spiking concentration. 
2.5.2 Preparation of blood products 
For the spiking experiments, PCs were divided into 5 x50 mL aliquots in PL 
1240 bags (Baxter Fenwal); 20 mL was kept in the original bag as a control. Spiked 
PCs (each containing approximately 1.6 x107 WBCs/pack) and control samples were 
held under standard PC storage conditions for 7 d. Five replicate RCCs were 
obtained, spiked, and held under standard storage conditions for 36 d (56). This 
shortened storage period (rather than the 42 d that is standard) was used as previous 
studies have found that bacteria that proliferate in stored RCCs do so before this time 
point (37, 100). A 20 mL portion from each RCC pack was kept under the same 
conditions as a negative control. 
2.5.3 Spiking procedure 
As bacteria can be easily introduced to the blood products through poor 
handling procedures, gloves worn for experimentation were prepared with 70% 
ethanol, and scissors used for cutting were treated with a sterile swab of 70% 
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isopropanol (Briemar). The side tubing of the blood bag was also prepared 
aseptically with a sterile swab of 70% isopropanol. A 1 mL volume of the prepared 
bacterial suspension was infused into each of the replicates, the tubing re-sealed by 
an Ultrasonic Tube Sealer (Terumo), and a sterile coupling device (Baxter Fenwal) 
was attached to the side tubing for ease of repeat sampling. The pack was inverted 
several times to ensure complete bacterial dispersion. Before sampling, the sterile 
coupling device was aseptically prepared by 70% isopropanol swab, and then a 1 mL 
sample was withdrawn using a 3 cc syringe (Terumo). Plate counts were performed 
on each replicate using 100 IaL duplicate samples to ensure accuracy of spiking. The 
negative control was sampled to confirm sterility at 0 d. 
2.5.4 Sampling of spiked and control products 
Spiked and control PCs were sampled (1 mL) aseptically at 24 hour intervals 
for 7 d. Spiked and control RCCs were sampled (1 mL) on d 0, 1 and 3, and then at 
3-d intervals to 36 d. While bacterial numbers were less than 104 CFU/mL, aliquots 
of 100 j_tL were spread in duplicate on BHI agar and incubated as described above. 
As bacterial numbers increased, 1 in 10 dilutions of 100 !IL samples were made in 
PBS and spotted onto BHIA in 10 pL duplicate aliquots. Any colour and physical 
changes (such as clumping) of blood products indicative of spoilage were also 
recorded. For RCCs, a positive spoilage result was recorded when pack darkening 
(indicative of RBC haemolysis) occurred. For PCs, a loss of swirling, an increase in 
product coudiness, or platelet clumping identified the spoiled components. 
2.6 DNA purification techniques 
2.6.1 Qiagen QIAMP DNA Mini Kit 
Bacterial extractions were conducted as per the manufacturer's instructions 
for Gram-positive bacteria (Protocol D). Purified DNA was eluted in 100 pL AE 
Buffer (supplied by the manufacturer) at 4°C. 
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2.6.2 BI0101 FastONA SPIN Soil Kit 
The manufacturer's extraction method was followed, and purified template 
was eluted into 100 !IL ddH20 for storage at 4°C. 
2.6.3 Novel rapid extraction method: bead-beating with spin column 
purification 
Bacteria were grown in 10 mL BHI broth with shaking at 37°C (except 
Y. enterocolitica and P. fluorescens, which were grown at 30°C) for 16 h and then 
pelleted by centrifugation at 3 500 xg for 5 mm. The supernatant was removed and 
the pellet resuspended in 2001.1,L lysis buffer (0.2 M NaH2PO41120, 0.2 M 
Na2HPO47H20 pH 7.0) (222), prior to being added to a 500 pl. screw-cap tube 
containing 120 [IL 250 micron glass beads (Sigma) and 25 pt MT buffer 
(Qbiogene). Samples were bead beaten for 180 s at setting 5.5 in a FastPrep FP101 
(Qbiogene ThermoSavant) to maximise cell lysis and DNA recovery. Machine 
cooling time (5 min) was allowed after 90 s. The tubes were briefly chilled on ice, 
and then centrifuged for 5 min at full speed to pellet large cellular debris. The 
recovered supernatant was placed in a fresh microfuge tube, to which 40 pi, of 
Proteinase K (Qiagen, supplied with the MiniKit) was added, the samples vortexed, 
and then incubated for a minimum of 1 h, with occasional mixing. Samples were 
centrifuged 5 min at 12 000 xg, and the supernatant placed in a fresh microfuge tube, 
to which 75 tL of potassium acetate (7.5 M) were added per 200 p,L of recovered 
supernatant. Samples were vortexed vigorously for 15 s and centrifuged 5 min at 
12 000 xg to precipitate the proteinaceous content, before the supernatant was 
removed to a fresh microfuge tube. Two hundred microlitres of RT 100% ethanol 
(BDH) were added to the supernatant and vortexed vigorously for 15 s. The 
purification of extracted DNA was carried out using columns and reagents from the 
Qiagen DNA MiniKit, according to the manufacturer's instructions. All 
centrifugation steps were carried out at RT at 12 000 xg, unless otherwise indicated. 
In brief, an appropriate amount of AE Buffer (supplied with the kit) was pre-warmed 
to 70°C in a heat block (Ratek). Each sample (including any white precipitate) was 
added to a spin column, and centrifuged for 1 min. The spin filter was placed in a 
fresh spin column collection tube, and AW1 buffer (500 tL, Qiagen) was added. 
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Samples were centrifuged for 1 mm, and the spin filter was placed into a fresh spin 
column collection tube. AW2 buffer (500 pL, Qiagen) was added to the column and 
the samples were centrifuged for 3 min. The spin column was placed in a fresh 
collection tube (not supplied with the kit), and re-centrifuged for 1 mm to remove all 
traces of the AW2 buffer and to dry the filter. The spin columns were then placed in 
a fresh collection tube (not supplied with kit), and 100 p,1_, of pre-warmed AE buffer 
was added directly to the filter and the samples incubated for at least 1 min at RT. 
Samples were then centrifuged for 1 min, and eluted DNA placed in a labelled 
screw-capped tube (Sarstedt) at 4°C for storage. 
For the extraction of bacterial DNA from contaminated blood products, the 
following steps were added prior to the bead beating step in the above method: A 
180 pi. volume of pre-lysis buffer (20 mM Tris-Cl pH 8.0, 2 mM EDTA, 1.2% 
Triton-X 100) (Qiagen Gram-positive lysis buffer, as per the manufacturer's recipe) 
was added to each sample which was then vortexed vigorously for 10 s. Following 
centrifugation (3 mm) the supernatant removed and the remaining pellet subjected to 
the above extraction procedure. 
2.6.4 Estimation of DNA concentration 
The absorbance of DNA at 260 nm was measured using an LKB-ultraspec-
plus-spectrophotometer (Pharmacia). An absorbance of 1.0 was equivalent to a 
concentration of 33 pg/mL of single-stranded DNA and 50 p.g/mL of double-
stranded DNA. 
2.7 Manipulation of DNA 
2.7.1 Restriction endonuclease digestion 
The restriction enzyme Rsal was obtained from Roche Applied Science and 
used to cleave DNA (PCR product) in the following typical reaction as 
recommended by the manufacturer: 0.5 to 2 pg DNA, 5 to 10 units of enzyme, one 
tenth volume of restriction buffer, and the appropriate amount of sterile ddH20 (20 to 
30 pi). The reaction was incubated at 37°C for 1 h, followed by 15 min at 70°C to 
52 
inactivate the enzyme. Complete cleavage of the target was checked by gel 
electrophoresis. 
2.7.2 DNA gel electrophoresis 
DNA was analysed by electrophoresis on 1.0 to 2.0% (wt/vol) agarose 
(Roche Applied Science) gels, using a Tris-acetate-EDTA (TAE) buffer system (pH 
8.0), and containing 0.5 1.1g/mL ethidium bromide to permit visualisation of the DNA 
on an ultraviolet (UV) light transilluminator. Prior to loading, DNA was mixed with 
sample loading buffer to give a final concentration of 10% (wt/vol) sucrose, 10 mM 
EDTA, and 0.01% bromophenol blue. Gels were run at 7.5 V/cm for 1 to 2 h, and 
then photographed using a Kodak Land Camera and Polaroid 667 film. 
2.8 Polymerase chain reaction 
2.8.1 Oligonucleotides 
Oligonucleotides used in this study were manufactured by GeneWorks Pty 
Ltd, Proligo, Sigma or Invitrogen and are listed in Table 2.3. Oligonucleotide 
sequences were obtained from published sources where indicated, or were designed 
using Primer3 software (http://biotools.umassmed.edu/bioapps/primer3  www.cgi), 
and were analysed using the BLASTN Algorithm at The National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov). Sequence comparisons 
of the 16S rDNA gene between species were conducted when necessary using the 
ClustalW (http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html)  program. 
2.8.2 Standard PCR 
The PCR method for the amplification of DNA was based on the method of 
Saiki (177). Template DNA was prepared as per Section 2.6.3. One to ten 
microlitres of template was used in each PCR. The 50 ilL PCR typically contained 1 
i_tM (each) oligonucleotide primer, 1 xPCR buffer (10 mM Tris-HC1, 50 mM KC1) 
(Applied Biosystems), 250 [tIVI (each) dNTP, 1.2 to 2.4 mM MgC12 (Applied 
Biosystems), and 1 U AmpliTaq GOLD DNA polymerase (Applied Biosystems). 
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Table 2.3: Oligonucleotides used during this study for PCR 
Name Target Sequence (5'-3) Reference 
1537r Human P-globin gene ACCACTTTCTGATAGGCAGC This Study 
GH20 Human P-globin gene GAAGAGCCAAGGACAGGTAC (175) 
KM29 Human p-globin gene GGTTGGCCAATCTATCCCAGG (175) 
PCO3 Human p-globin gene ACACAACTGTGTTCACTAGC (175) 
PC04 Human p-globin gene CAACTTCATCCACGTTCACC (175) 
RS40 Human p-globin gene ATTTTCCCACCCTTAGGCTG (175) 
RS42 Human p-globin gene GCTCACTCAGTGTGGCAAAG (175) 
RS80 Human p-globin gene TGGTAGCTGGATTGTAGCTG (175) 
644bp of the Y. enterocolitica 
11A 
pYV virF gene 
AAGGTTGTTGAGCATTCACAAGATGG (192) 
644 bp of the Y. enterocolitica 
12A 
pYV virF gene 
TTTGAGTGAAATAAGACTGACTCGAGAACC (192) 
mecl 550 bp of the mecA gene AAAATCGATAAAGGTTGGC (15) 
mec2 550 bp of the mecA gene AGTTCTGGCACTACCGGATTTGC (15) 
Al 330 bp of the all gene TTAATGTGTACGCTGGGAGTG (206) 
A2 330 bp of the all gene GGAGTATTCATATGAAGCGTC (206) 
TStaG422 317 bp of the tuf gene GGCCGTGTTGAACGTGGTCAAATCA (125) 
TStag765 317 bp of the tuf gene TIACCATTTCAGTACCTTCTGGTAA (125) 
ymoACR 292 bp of the ymoA gene GACTTTTCTCAGGGGAATAC (83) 
292 bp of the ymoA gene 
ymoaDF GCTCAACGTTGTGTGTCT (83) 
Universal 16S rDNA target: 
DG74 AGGAGGTGATCCAACCGCA (86) 
313 bp with both 143 and 68d 
143 Gram-positive 16S rDNA target GAYGACGTCAARTCMTCATGC (112) 




Universal 16S: 333bp with 
65ab AACTGGAGGAAGGTGGGGAY (112) 
DG74 
27f 1420 bp of the16S rDNA gene AGAGTTTGATAATGGCTC (115) 
1492r 1420 bp of the16S rDNA gene GGGCGGTGTGTACAAGGC (115) 
16SF 466 bp of the 16S rDNA gene TCCTACGGGAGGCAGCAGT (141) 
16SR 466 bp of the 16S rDNA gene GGACTACCAGGGTATCTAATCCTGTT (141) 
Degenerate base code: N = G, A, C or T; D = G, A, or T; H = A, T, or C; K = G or T; M = A or 
C; R = A or G; S = C or G; V= G, A or C; W = A or T; Y = T or C; I. Inosine. 
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The cycle conditions varied for each PCR (but each was conducted for 50 
cycles), and are detailed in following sections. Following PCR, an aliquot of each 
sample (10 fiL) was analysed by agarose gel electrophoresis. 
2.8.2.1 	PCR of the human 0-globin gene 
PCR of the human 13-globin gene was used to test the intactness of the 
purified template. This utilised the primers and method of Saiki (177) (Table 2.3) 
which targeted a range of amplicon sizes. The 1537r primer was novel to this study. 
2.8.2.2 PCR of the Y. enterocolitica pYV gene virF 
The pYV-located virF gene was amplified using the method and primers of 
Thisted Lambertz (194). 
2.8.2.3 Gene-specific PCRS 
The gene (mecA) was selected for detection of a methicillin resistant 
S. aureus with the primers and method of Barski (15). 
The 1'. enterocolitica ail gene PCR was performed using the primers and 
method of Wannet (208). This PCR had been used to detect Y. enterocolitica in 
food. 
2.8.2.4 Genus-specific PCRs 
The tufPCR (for all staphylococcal spp.) which targets the staphylococcal 
elongation factor Tu (EF-Tu) used the primers and method of Martineau (127). 
The yersinial target ymoA was selected for study with the primers and method 
of Grant (85). 
2.8.2.5 Gram-positive and Gram-negative PCRs 
The 16S Gram-positive and Gram-negative PCRs were both conducted using 
the method of Klausegger (114). They used a generic 16S primer (DG74), paired 
with a Gram-positive (143) or Gram-negative (68d) specific primer. 
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2.8.2.6 16S universal PCR - 333 bp 
The 333bp 16S universal PCR was conducted with the primers DG74 and 
68d and method of Greisen (88). 
2.8.2.7 16S universal PCR - 1361 bp 
The 16S Gram-positive and Gram-negative PCRs were both conducted in the 
method of Lane (117). All reagents and plasticware used for universal PCR were 
UV treated prior to the addition of template DNA. 
2.8.3 Real-time PCR 
Real-time PCR was conducted in a Rotor-Gene (Corbett Research), using 
SYBR-green chemistry. The gain was set to a value of 4 for each run, and the 
acquisition step varied depending on the PCR (see following sections). A melt 
profile was conducted at the end of the final extension. Template DNA was prepared 
as per Section 2.6.3. Five microlitres of template were used in each PCR. If 
necessary, an aliquot of PCR reaction (10 pL) was analysed by agarose gel 
electrophoresis. Real time results were analysed using RotorGene 4.6 software 
(Corbett Research). 
2.8.3.1 Home-made SYBR green mix 
The 20 !IL PCR reaction also contained 2 p.M (each) oligonucleotide primer, 
1 xPCR buffer (10 mM Tris-HC1, 50 mM KC1) (Applied Biosystems), 250 jIM 
(each) dNTP, 1.2 to 2.4 mM MgC12 (Applied Biosystems), 1 U AmpliTaq GOLD 
DNA polymerase (Applied Biosystems) and SYBR green (supplied at 10 000x and 
diluted with ddH20 to 1 in 30 000 for use, Molecular Probes). 
2.8.3.2 lnvitrogen Platinum SYBR Green qPCR SuperMix UDG 
The PCR SuperMix contained 20 mM Tris-HC1 (pH 8.4), 50 mM KC1, 
200 [tM dGTP, 200 jiM dATP, 20011M dCTP, 400 gM dUTP, 1 U UDG, 3 mM 
MgC12 (Applied Biosystems), 1.5 U Platinum Taq DNA polymerase and SYBR 
green, to which 10 gM (each) oligonucleotide primer was added. Three microlitres 
of template was added to each sample. 
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2.8.3.3 16S universal PCR 
The method and primers of Nadkarni (143) were selected for detection of the 
16S gene. Initially, a home-made mastermix (Section 2.8.3.1) was used, but then 
replaced in favour of a commercially available mastermix (Section 2.8.3.2). The 
cycles were increased to 50 to maximise the sensitivity of the PCR, and the gain was 
calibrated for each run (usually set to 6). 
2.9 DNA sequencing 
2.9.1 Preparation of DNA template 
PCR product DNA was purified for sequencing using the Qiaquick PCR 
Purification Kit (Qiagen), according to the manufacturer's instructions. 
2.9.2 Sequencing reactions 
Determination of nucleotide sequence was performed by cycle sequencing 
using the ABI PRISMTm BigDye Terminator Cycle Sequencing Ready Reaction Kit 
Version 3, according to the manufacturer's directions (Applied Biosystems). PCR 
product (10 to 100 ng), was used as template in a 20 RI„ reaction with 4 iL of 
Terminator Ready Reaction Mix and 3.2 pmol (PCR template) oligonucleotide 
primer. Sequence reactions containing PCR product were subjected to 25 cycles of 
96°C for 10 s (denaturation), 50 °C for 5 s (annealing) and 60°C for 4 min (extension) 
using a GeneAmp PCR system 9700 (Applied Biosystems). Extension products 
were purified by ethanol precipitation. The 151.1.I. reaction mixture was combined 
with 25 RL distilled water, 4 RI„ of 3 M sodium acetate (pH 4.6), and 100 III of 95% 
ethanol and placed on ice for 10 tnin. After centrifugation at 12 000 xg for 30 min, 
the pellet was washed with 500 RI, of 70% ethanol and dried at 80 °C. Amplification 
products were run on an ABI 3730 automated capillary DNA sequencer (Applied 
Biosystems). 
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2.9.3 Analysis of sequence data 
PCR products were sequenced in both directions, and submitted to the 
BLASTN Algorithm for analysis at The National Centre for Biotechnology 
Information. Sequence comparisons of the 16S rDNA gene between species were 
conducted when necessary using the CLUSTALW program. 
2.10 Polymerase chain reaction — enzyme linked immuno assay 
2.10.1 Biotinylated oligoprobes for PCR-ELISA 
Probes used in the PCR-ELISA dig kit were purchased ready-made with a 
5' biotin label from Proligo (Table 2.4). Oligoprobe sequences were obtained from 
published sources where indicated, or were designed using Primer3 software, 
following alignment and analysis of 16S sequence using CLUSTALW to find unique 
sequences for probing. 
2.10.2 Digoxigenin-labelling of PCR products 
Double-stranded DNA fragments (50 to 500 ng) were labelled with 
digoxigenin-11-dUTP (DIG) according to the manufacturer's instructions (Roche 
Applied Science). DIG-labelled DNA was stored at -20 °C. 
2.10.3 Hybridisation and washing conditions 
PCR-ELISA was conducted using the Roche PCR-ELISA DIG-Detection kit 
Roche Applied Science), according to the manufacturer's protocol A instructions 
Briefly, in a 96-well plate DIG-labelled PCR product (usually 5 lit) was added to 
20 p.L Solution la (Denaturation solution, vial 1), which was then mixed and 
incubated for 10 min at RT. The volume of each sample was adjusted to 250 jiL by 
adding the appropriate amount of solution 2a (Hybridisation solution with 7.5 
pM/mL biotinylated probe), followed by vortexing. A 200 !IL volume of each 
sample was pipetted into the MTP strips supplied with the detection kit (streptavidin 
coated). The plates were sealed with cover foils (supplied with the kit) and incubated 
at 55°C for 30 min with shaking. 
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Table 2.4: Biotinylated oligoprobes used in this study for 
PCR-ELISA 
Name 16S Target 
	





















group B streptococcus 
K. oxytoca 
P. aeruginosa 
group B streptococcus 
S. aureus 
Strep. pneumoniae 
group A streptococcus 
Streptococcus spp. 
*GAACAAGTGCTAGTTGAATAAGC This study 







*GAACGTTGGTAGGAGTGG This study 
*GAAGGGAGTGAGGTTAATAACC This study 








Degenerate base code: N = G, A, C or T; D = G, A, or T; H = A, T, or C; K = G or T; M = A or 
C; R = A or G; S = C or G; V = G, A or C; W = A or T; Y = T or C. * indicates biotin tag at 5' 
end. 
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The hybridisation solution was removed, and the plate washed five times with 
250 gL solution 3a (washing solution, working solution) by aspiration. After the 
final washing, plates were tapped dry on lint-free cloths. A 200 !IL volume of 
solution 4a (anti-DIG-POD working solution) was added to each well and the plate 
incubated for 30 min in the dark at 37°C with shaking. The anti-DIG-POD solution 
was removed, and the plate was again washed five times with 250 !IL solution 3a by 
aspiration. After the final wash, plates were tapped dry on lint-free cloths. A 200 ilL 
volume of ABTS solution (vial 6) was added to each well, and the plate incubated in 
the dark for 30 min with shaking at 37°C. Plates were read at 405 nm on a 
spectrophotometer (Biorad 3550). The results were then subtracted from the 
negative controls and plotted. 
2.11 Southern dot blot 
2.11.1 Design of oligoprobes 
Oligoprobes used in this study were manufactured by Proligo and are listed in 
Table 2.5. Oligonucleotide sequences were obtained from published sources where 
indicated, or were designed using CLUSTALW alignments and BLASTN analysis of 
bacterial 16S gene sequences, and the Primer3 program. 
2.11.2 Reverse-Southern dot blot 
2.11.2.1 Digoxigenin-labelling of PCR products 
Double-stranded DNA fragments (50 to 500 ng) were labelled with 
digoxigenin-11-dUTP (DIG) according to the manufacturer's instructions (Roche 
Applied Science). DIG-labelled DNA was stored at -20 °C. 
2.11.2.2 Poly dT tailing of oligonucleotides 
Where necessary, oligonucleotide probes were poly dT tailed using the Roche 
DIG Oligonucleotide Tailing Kit (Roche Applied Science), with standard dNTPs 
(Roche Applied Science) instead of the supplied DIG-labelled dNTPs, according to 
the manufacturer's instructions. 
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Table 2.5: Oligoprobes used in this study for Southern dot blot 
Name 16S Target Sequence (5'-3) Reference 
143+3 Gram-positive bacteria GGAYGACGTCAARTCMTCATGC This study* 
Bcerl B. cereus AAGAGCTGCAAGACCGCGAG This study 
Enc131 Enterococcus spp. CCCCTTCTGATGGGCAGG (17) 
Entero1 Family Enterobacteriaceae CTCGCGAGAGCAAGCGGAC This study 
N6R Gram-negative bacteria GGTGCCTTCGGGAAC (42) 
Paer1 P. aeruginosa GCCTTGACATGCTGAGAACTTTCC This study 
Ppunew5r Pseudomonas genus GGGTTGCCAAGCCGCGTG This study 
Saga group B streptococcus GTAAACACCAAACMTCAGCG (195) 
Saur2 S. aureus GAAGCAAGCTTCTCGTCC (106) 
SP16SR Universal 16S CTACGCATTTCACCGCTACAC (90) 
Spy3 group A streptococcus TTCCAAAGCGTACATTGGTTGAGC This study 
Staph3 Staphylococcus genus CTTACACATTTGTTCTTCCCTAATAACAG This study 
Strep. mitis/ 
STREP16SR GTACCGTCACAGTATGAACTTTCC (51) 
Strep. pneumoniae 
Yent2 Y. enterocolitica ACTCTTGACATCCACGGAATTTAGC This study 
Degenerate base code: N = G, A, C or T; D = G, A, or T; H = A, T, or C; K = G or T; M = A or 
C;R=AorG;S=CorG;V=G,AorC;W=AorT;Y=TorC. 
* Derived from oligonucleotide 143 (see Table 2.3). 
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2.11.2.3 Binding of oligoprobes to the nylon filters 
One microlitre aliquots of appropriately diluted (between 0.2 and 50 pM) 
oligonucleotide probes were spotted in duplicate onto Hybond-N+ nylon membrane 
(Amersham Biosciences). The oligoprobes were fixed to the membrane with a 
Spectrolinker XL-1000 UV crosslinker (Spectronics Corporation). 
2.11.2.4 Probing of nylon filters 
The DIG-labelled PCR products were added to DIG Easy Hyb Buffer (Roche 
Applied Science) and denatured by boiling. Prehybridisation was performed for at 
least 2 h at between 40 and 60°C (depending on the experiment). Membranes were 
hybridized overnight with the DIG-labelled PCR product and with gentle agitation at 
the same temperature selected for pre-hybridisation. The membranes were then 
washed twice with 2 xSSC, 0.1% (wt/vol) SDS for 5 min at RT, followed by 2 
washes with TMAC buffer (3 M tetramethylammoniumchloride, (TMAC), 50 mM 
TrisC1 pH 8, 0.2 mM EDTA, 0.1% wt/vol SDS) at 40°C for 15 min. Blocking 
solution was added and the membrane incubated at RT for 30 min. 
2.11.2.5 DIG detection 
After blocking, hybridised DIG-labelled PCR product was detected with 
alkaline phosphatase conjugated anti-digoxigenin antibody, and 5 to 15 min after the 
addition of the chemiluminescent alkaline phosphatase substrate, CDP-Star (Roche 
Applied Science), membranes were exposed to Kodak BioMax Light Film. Films 
were developed using an automated X-ray film developer (Kodak). 
2.11.3 Standard-Southern dot blot 
2.11.3.1 3' Digoxigenin end labelling of oligonucleotides 
Oligonucleotide probes were DIG-labelled using the Roche DIG 
Oligonucleotide Tailing Kit (Roche Applied Science), according to the 
manufacturer's instructions. 
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2.11.3.2 Binding of PCR products to the nylon filters 
One microlitre aliquots (50 to 100 lig of template) of PCR product were 
spotted in duplicate onto Hybond-N+ nylon membrane (Amersham Biosciences). 
These were fixed to the membrane with a Spectrolinker XL-1000 UV crosslinker 
(Spectronics Corporation). Where necessary, these PCR products were purified with 
the Qiagen QIAquick PCR Purification Kit (Section 2.9.1) prior to their application 
to the nylon membrane. 
2.11.3.3 Probing of nylon filters 
The DIG-tailed oligoprobes were each added to DIG Easy Hyb Buffer (Roche 
Applied Science) at a concentration of 10 pM/p.L. Prehybridisation was performed 
for at least 2 hours at 50°C. Membranes were hybridised overnight with the DIG-
labelled oligoprobe and with gentle agitation at 50°C. The membranes were then 
washed twice with 2 xSSC, 0.1% (wt/vol) SDS for 5 min at RT, followed by 2 
washes with 0.1 xSSC, 0.1% (wt/vol) SDS at 50°C for 15 min. Blocking solution 
was added and the membrane incubated at RT for 30 min. 
2.11.3.4 DIG detection 
After blocking, hybridised DIG-labelled oligoprobe was detected with 
alkaline phosphatase conjugated anti-digoxigenin antibody, and 5 to 15 min after the 
addition of the chemiluminescent alkaline phosphatase substrate, CDP-Star (Roche 
Applied Science), membranes were exposed to Kodak BioMax Light Film. Films 
were developed using an automated X-ray film developer (Kodak). 
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CHAPTER THREE 
SURVIVAL AND PROLIFERATION OF 
BACTERIAL CONTAMINANTS IN 
BLOOD COMPONENTS PRODUCED BY 
THE BUFFY COAT METHOD 
3.1 	Introduction 
Prospective screening has revealed a diverse range of bacteria contaminating 
blood products (14, 20, 26, 65, 116, 119, 128, 174, 175, 225). Although they are 
generally introduced into the products at low numbers (7, 24, 57, 76, 78, 201), little 
is known about their behaviour in these during storage, or how long it takes them to 
reach numbers of risk to recipients. Additionally, not all bacteria identified during 
screening have been associated with patient sepsis, and it has not been determined 
whether cases involving these species have simply failed to be recognised, or 
whether they are unable to proliferate to significant numbers during product storage. 
Some studies of bacteria spiked into products manufactured by the platelet rich 
plasma (PRP) method have been published (160, 199), but these products are not 
widely used in Australia and differ significantly from the those which are, a process 
known as the buffy coat method. A review of these products can be found in Section 
1.2.3, but most importantly, buffy coat products contain fewer WBCs and little 
natural plasma. Little is known about what effects the current practices of reducing 
WBCs and plasma (hence complement) in products, has on the ability of bacteria to 
grow and survive, although it is hypothesised that buffy coat products may have a 
lesser ability to prevent bacterial outgrowth. We therefore wished to: 
1. Determine the behaviour of bacteria deliberately spiked into buffy coat PCs and 
RCCs; 
2. Evaluate if the bacteria can survive and grow in these storage environments; 
3. Determine how few microorganisms are required for detectable bacterial 
outgrowth; and 
4. Determine which bacteria are of risk to patients (and hence worth screening for by 
means of a rapid detection method). 
To this end, growth kinetic studies of bacteria in stored buffy coat blood 
products were undertaken. 
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3.2 Selection of bacteria for study 
It was impractical to study all contaminant species in blood products for their 
growth kinetics. Subsequently, published (164, 200) and ARCBS survey data were 
used to categorise each into four main groups, and representatives of each category 
were selected for study. The groups identified and bacteria chosen to represent them 
were: psychrophilic, environmental opportunist (P. fluorescens); mesophilic, 
environmental opportunist (P. aeruginosa); psychrophilic enteric (Y. enterocolitica 
03); and skin flora (S. aureus and S. epidermidis). All of these species have been 
reported as causing transfusion-associated fatalities, and where possible, isolates 
from such cases were used (116, 136, 182, 200) Y. enterocolitica serotype 03 was 
chosen for study, as this serotype has been most commonly implicated in 
Y. enterocolitica transfusion incidents in Australia and New Zealand (68, 109, 123). 
The presence pYV in the Y. enterocolitica strain 67R was confirmed by PCR at the 
time of spiking (not shown). The identity of all isolates was confirmed by using a 
VITEK system. 
Fresh bacterial cultures and the blood products were prepared as per Sections 
2.5.1 and 2.5.2. PCs contained 8 x107 WBCs/pack, whilst RCCs contained 
—108 WBCs/pack. 
3.3 Platelet concentrates 
The growth curves of P. fluorescens, P. aeruginosa, S. epidermidis, S. 
aureus, and Y. enterocolitica in PCs are shown in Figure 3.1. The actual bacterial 
inocula for the 102 CFU/mL experiments were 115, 108, 35, 130, and 334 CFU/mL, 
for P. aeruginosa, P. fluorescens, S. aureus, S. epidermidis, and Y. enterocolitica, 
respectively. The actual bacterial inocula for the 10 CFU/mL experiments were 13, 2, 
8, 17, and 37 CFU/mL, for P. aeruginosa, P. fluorescens, S. aureus, S. epidermidis, 
and Y. enterocolitica, respectively. As few as 5 CFU/mL of these bacteria grew to 
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Figure 3.1: Bacterial growth in stored (22±2°C, 7 d) 
platelet concentrates 
Vertical lines indicate when product spoilage (loss of swirling, platelet 
aggregates or product cloudiness) became evident. 
P. fluorescens displayed logarithmic growth soon after spiking, and peaked at 10 8 
CFU/mL within 2 d. P. aeruginosa displayed similar, although slightly slower 
growth, achieving 10 8 CFU/mL in 2.5 d. S. aureus and S. epidermidis proliferated 
more slowly than the pseudomonads, and achieved 107 CFU/mL by 3 d. The 
Y enterocolitica strain 67R commenced logarithmic growth after 24 h. All bacteria 
that proliferated achieved maximal numbers at around 4 d. Gram-negative bacteria 
peaked at approximately 109 CFU/mL, whereas S. aureus and S. epidermidis 
achieved were between 107 and 108 CFU/mL. The growth curves obtained for each 
species at both inocula tested were similar. 
3.3.1 Spoilage of platelet concentrates 
All species that proliferated caused spoilage of PCs (indicated by the vertical 
dotted lines), but this was not evident until after 3 d when the Gram-positive bacteria 
had reached 106 CFU/mL, and the Gram-negative bacteria were around 10 8 CFU/mL. 
Of the bacteria tested, only the Staphylococcus spp. induced the formation of platelet 
aggregates in PCs. For S. epidermidis, numerous aggregates of 3 mm diameter were 
seen (not shown). For S. aureus, aggregates consisted of one or two large clumps of 
10 to 40 mm in diameter (Fig 3.2b). In PCs containing the other bacterial species, an 
increase in the 'cloudiness' of the pack was observed (Figure 3.2c). A lack of PC 
swirling was evident in all highly contaminated PCs, regardless of the other 
indicators of spoilage observed. Absence of swirling was observed in some control 
PCs at 7 d, although sampling revealed that these remained sterile. 
3.4 Red cell concentrates 
The actual bacterial inocula for the 10 3 CFU/mL experiments were, 481, 906, 
and 1360 CFU/mL for P. aeruginosa, S. aureus and S. epidermidis, respectively. 
The starting inocula for the 102 CFU/mL experiments were 69, 113, 449, 34, and 377 
CFU/mL for P. aeruginosa, P. fluorescens, S. aureus, S. epidermidis, and 
Y. enterocolitica, respectively, whilst the starting for the 10 CFU/mL experiment 
were 7, and 32 CFU/naL for P. fluorescens and Y. enterocolitica, respectively (Figure 






Figure 3.2: Spoilage markers of platelet concentrates 
a) Control PC. 
b) Contaminated PC containing -10 8 CFU/mL S. aureus. 
The arrow indicates aggregate of - 3 cm diameter. 
c) Contaminated PC containing -10 8 CFU/mL 
P. aeruginosa, showing product cloudiness. 
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Figure 3.3: Survival and growth of bacteria in stored 
(4±2°C, 36 d) red cell concentrates 
Vertical lines indicate when product spoilage (pack darkening due to red 
cell haemolysis) became evident. 
However, only the psychrophilic species (Y. enterocolitica and P. fluorescens) 
proliferated, with both microorganisms reaching stationary phase by around 12 d. 
Fewer than 10 CFU/mL of Y. enterocolitica and P. fluorescens were able to initiate 
growth which began after a 24 h lag period. In contrast, the numbers of 
P. aeruginosa, S. aureus and S. epidermidis declined within the first 6 d of spiking. 
As a result, these bacteria were not recovered on several occasions during the early 
period of experimentation, but were isolated at later time-points in low numbers 
(approximately 5 CFU/mL), indicating they survived extended product storage under 
standard conditions. The proliferative patterns of the psychrophiles did not appear to 
be influenced by the size of the inoculum. However, the Gram-positive organisms 
appeared to survive slightly more efficiently (102 to 103 CFU/mL) when spiked at the 
higher 103 CFU/mL dose, compared with the lower 102 CFU/mL dose (survival at 5 
to 10 CFU/mL). P. aeruginosa survival was unaffected by the size of the inoculum. 
3.4.1 Spoilage of red cell concentrates 
There was no evidence of spoilage in products spiked with the species that 
survived, but did not proliferate (Figure 3.4a). The actively proliferating species did, 
however, cause the characteristic pack darkening indicative of spoilage (Figure 3.4b). 
For P. fluorescens, spoilage of RCCs (indicated by the vertical dotted lines on the 
growth plots) was evident at 6 d (10 7 CFU/mL), and for Y. enterocolitica at 9 d (107 
and 108 CFU/mL). 
3.5 	Y. enterocolitica 
Despite reports linking TTBS to Y. enterocolitica-contaminated PCs, this 
species had previously been reported as unable to proliferate in these products. 
Therefore, we wished to determine the contribution of the anti-host 70 kb virulence 
plasmid, pYV, to survival and growth of this species in stored buffy coat PCs, as this 
plasmid may be lost during growth of bacterial cultures for spiking (which may have 
occurred in previous studies). 
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a 
Figure 3.4: Spoilage markers of red cell concentrates 
a) Control RCC. 
b) Contaminated RCC containing -108 CFU/mL P. fluorescens. 
Note the extensive haemolysis and pack darkening. 
We also wished to evaluate the role of pYV in the survival and growth of 
Y. enterocolitica in RCCS. To this end, a virulence plasmid-less (67W) variant of 
Y. enterocolitica 03 strain 67 was subsequently studied in stored buffy coat PCs and 
RCCs, and its behaviour compared with that of the parental strain. 
3.5.1 Platelet concentrates 
The actual spiking numbers of 1'. enterocolitica strain 67W were 45 and 3 for 
the 102 CFU/mL and the 10 CFU/mL experiments, respectively. The pYV+ 
Y. enterocolitica strain 67R commenced logarithmic growth after 24 hours, whereas 
the pYV- Y. enterocolitica strain 67W was unrecoverable after 3 d (Figure 3.5a). 
Spoilage was only evident in the 67R-spiked PCs at 3 to 4 d (10 8 CFU/naL) 
3.5.2 Red cell concentrates 
The actual spiking numbers of Y. enterocolitica strain 67W were 40 and 8 for 
the 102 CFU/mL and the 10 CFU/mL experiments, respectively. The growth curves 
of both strains of 1'. enterocolitica were identical (Figure 3.5b). Presence or absence 
of pYV in the Y. enterocolitica strains did not appear to affect the time-point at 
which spoilage occurred, nor the number of bacteria required to cause it. 
3.6 Discussion 
The bacterial behavior observed in stored buffy coat PCs suggests that these 
products have reduced antimicrobial activity, compared to plasma-rich PCs. Not 
only did some bacterial contaminants survive throughout blood product storage, but 
some species also proliferated to reach high numbers without producing physical 
evidence of contamination. The introduction of even small numbers of bacterial 
contaminants (less than 10 CFU/mL) into buffy coat PCs and RCCs may provide an 
opportunity for bacterial outgrowth. In buffy coat PCs, we observed maximum 
counts of the Gram-positive species 1 to 2 d earlier, and the Gram-negative species 1 
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Figure 3.5: Survival and growth of pYV+ and pYV-
Y. enterocolitica strains in blood products 
a) PCs 
b) RCCs 
Vertical lines indicate when product spoilage became evident. 
Likewise, the proliferation of S. epidermidis and S. aureus (with inocula of 7 and 85 
CFU/mL, respectively) to stationary phase in PRP PCs in a study by Braine (31) was 
slower than in the buffy coat PCs used in this study. However, it is possible that 
strain variation may be partially responsible for these observations, as other studies 
using the same species of bacteria have shown similar results to ours (46, 201). As 
the average age of transfused PCs is estimated to be 3 to 4 days old, it is concerning 
that contaminated products may have already reached significant clinical levels by 
this stage, although they do not show the physical indicators of extreme 
contamination. Certainly, many instances of TTBI and sepsis have been recorded 
following transfusion of PCs of this age, and with no apparent indicators of 
contamination. It is, therefore, imperative that another means of identifying these 
contaminated products and removing them from the supply is developed. 
A consistent finding of our study of spiked buffy coat-reduced RCCs was that 
the bacteria within these remained viable for at least 36 d. Bacteria which grew at 
low temperatures proliferated rapidly to high numbers, whereas other species 
persisted in low numbers. Whilst highly contaminated RCCs pose obvious risks, 
there is increasing clinical evidence that lower numbers of bacteria may also be of 
concern, particularly in immunocompromised patients. Although most TTBI/deaths 
from bacterially contaminated RCCs are associated with rapidly growing 
psychrophiles (200), other bacteria, such as S. aureus and S. epidermidis, have also 
been implicated in patient deaths (116, 164, 216, 217). In these instances, the 
presence of superantigens (140) or other bacterial toxins may play a role in the 
pathogenesis of the disease. Alternatively, the combination of a small number of live 
bacteria and the remnants of dead bacteria (such as occurs in a patient undergoing 
antibiotic therapy and who subsequently receives a contaminated product) may be 
sufficient to exert the same effect. Cytolcines produced during product storage may 
also be important in transfusion-related sepsis, but the low number of WBCs 
contained within buffy coat-reduced RCCs, and the low temperature conditions of 
storage are likely to limit this. 
In contrast to our results, other published studies have failed to show 
proliferation of Y. enterocolitica in stored PCs (38, 201). We have demonstrated in 
repeated experiments that survival and growth of Y. enterocolitica in PCs requires 
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the virulence plasmid, pYV, which confers serum resistance and resistance to 
phagocytosis. It also appears that despite the reduced amount of WBCs and 
complement in these products, the plasmid-less Y. enterocolitica strain 67W 
remained sensitive to killing. Therefore, despite the reduced presence of 
antibacterial mechanisms in PCs, bacterial species and strains classified as sensitive 
to serum and/or phagocytic killing may still be cleared from these products. 
Plasmid-less Y. enterocolitica strains readily occur spontaneously in vitro, 
particularly when the bacteria are cultivated at 37°C. Hence, it seems likely that 
other investigators may have grown pYV- strains of this species, although there is 
also the possibility some variation in survival between 0-types (serotype 08 was 
more frequently studied elsewhere). Regardless of the mechanism of bacterial 
survival, the importance of Y enterocolitica contamination of stored PCs was 
emphasised by reports of PC-related fatalities attributable to Y. enterocolitica sepsis 
(55, 97, 109, 116, 164, 181, 200). 
Although pYV was required for Y. enterocolitica survival in PCs, this was 
not the case in stored buffy coat RCCs. Indeed, the similar growth curves of the 
pYV+ and pYV- strains in RCCs established that pYV does not influence the 
survival or proliferation of this species in buffy coat RCCs. The non-requirement of 
pYV for the survival of Y. enterocolitica in RCCs can be explained by the low levels 
of WBCs and plasma, and/or by reduced antimicrobial activity during refrigeration. 
Although pYV- bacteria are ill-equipped to survive in the recipients of contaminated 
blood, the amount of endotoxin produced during storage still poses a significant 
hazard (7, 134, 136). 
There is, therefore, a need for a rapid and more sensitive screening technique 
to ensure a blood supply free from bacterial contamination. With the data available 
from this and previous studies, all contaminants should be considered of potential 
risk in one or more products, and should therefore be screened universally. Methods 
by which this might be achieved, were therefore evaluated. 
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CHAPTER FOUR 
DEVELOPMENT AND EVALUATION OF 
RAPID METHODS FOR THE 




More than 35 species of bacteria have to date been found to contaminate 
blood products (14, 20, 26, 65, 116, 119, 128, 174, 175, 225). The findings of 
Chapter 3 suggest that ideally, all bacteria should be detected and the product 
removed from the blood supply. It also showed that 10 CFU/mL may quickly 
proliferate to reach high numbers (>10 5 CFU/mL) in buffy coat products in as little 
as 2 to 3 d for PCs, and less than 12 d for RCCs, without being identifiable by visual 
inspection. For these reasons, contamination must be detectable at less than10 3 
CFU/mL, well before there is a significant risk to patients. As few bacteria are 
present during WB collection, detection is likely to be more successful if it occurs 
close to the time of transfusion. 
Molecular methods such as PCR are increasingly being used to detect the 
presence of bacteria in a range of settings, from specific targeting of species, to 
generic amplification of all bacteria using conserved 16S ribosomal sequences (104, 
176). Blood-banking institutions have recognised the potential of molecular methods 
by implementing nucleic acid testing (NAT) to complement their serological 
screening procedures for viruses. For these reasons, the molecular method of 16S 
PCR was selected for further investigation in this study. Yersinia enterocolitica 
(ATCC 23715) and Staphylococcus aureus (ATCC 25923) were chosen for initial 
evaluation of the detection method. Both are clinically significant contaminants of 
blood products, were able to survive and/or proliferate in the kinetic experiments in 
this study (Chapter 3), and allowed us to test the efficacy of our extraction and 
detection methods on both Gram-positive and Gram-negative species. After the 
initial establishment of our methods with these species, the range of bacteria was 
expanded to more then 30 species and strains found in blood products (Table 2.2). 
4.2 Selection and development of a DNA extraction method 
The screening of blood products for bacteria requires a high-throughput, rapid 
extraction method that can be conducted as simply and safely as possible. 
Furthermore, to ensure suitable sensitivity of the PCR assay, we need to effectively 
extract the nucleic acid from as many bacteria as possible from each sample. 
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Initially we examined the possibility of using commercial kits to extract 
DNA, as many such kits are available to obtain bacterial DNA from various sample 
types. The desired sensitivity of the PCR was set to 10 3 CFU/mL. If a 10 !IL aliquot 
of prepared 100 pL template (from an original 1000 [iL sample) is used, this equates 
to 100 CFU/reaction. 
4.2.1 Qiagen 01Amp DNA Mini Kit 
The Qiagen DNA Mini Kit is recommended for extracting DNA from both 
prokaryotic and eukaryotic cells, particularly in the presence of blood and blood 
products. The method for extraction of bacterial DNA involves several additional 
steps, as the bacterial cell wall is more difficult to lyse than the eukaryotic cell 
membrane. As the objective was to obtain bacterial DNA from both Gram-negative 
and Gram-positive species, the manufacturer's instructions for Gram-positive 
bacteria were used as these are more resistant to lysis (also see Chapter 2, Section 
2.6.1). Initially, the method was evaluated using pure cultures, and then tested 
against spiked PCs and RCCs. Twenty microlitre pellets of starting material were 
used, and of the 100 p,L eluted template, 10 pL was examined by electrophoresis 
(Figure 4.1a). Unfortunately, whilst some template DNA was recovered from 
S. aureus, the amount was much less than the amount obtained from Y. 
enterocolitica. Extension of the lysis buffer step to an overnight incubation, and 
varying the amount of lysozyme and lysostaphin in each reaction, did not enhance 
the yield (results not shown). Furthermore, the requirement of an overnight 
incubation step significantly slowed the extraction process, and our preferred sample 
volume of 1000 !IL was unable to be processed, due to repeated clogging of the spin 
filter membranes. 
Hence, it was apparent that this kit would not meet our needs, and a 












a 	 b 
Figure 4.1: Kit extraction of bacterial DNA from washed cells 
The source of DNA is shown above each lane. 
a) Qiagen Mini Kit Protocol D for Gram-positive bacteria. 
b) FastDNA SPIN Kit for Soil. 
4.2.2 BIO 101 FastDNA SPIN Kit for soil 
'Bead-beating' using tubes containing ceramic or glass beads or garnet 
powder, facilitates the release of DNA using ballistic disintegration of the cells in a 
milling machine. This has been shown to rapidly lyse a majority of cell types, and 
many samples can be processed simultaneously (29, 224). The BI0101 FastDNA 
SPIN Kit with the FastPrep bead-beating machine was chosen for evaluation. These 
have been successfully applied to soil samples containing bacteria, which like our 
blood products, are rich in particulate matter. This kit was used in accordance with 
the manufacturer's instructions (as detailed in the Materials and Methods chapter, 
Section 2.6.2), which are briefly described here. 
Approximately 20 p,L pellets of pure culture were processed (or known 
quantities of bacteria spiked into RCC or PC), and 10 gL of 100 pL of template 
eluent was examined by gel electrophoresis. As shown in Figure 4.1b, this kit 
successfully produced more DNA from pure cultures than the Qiagen kit, but just 
half of our target volume of 1000 pL of blood product could be processed in this 
way. Furthermore, the cellular debris from the RCCs caused the spin column 
membrane to repeatedly clog and rupture (hence little DNA recovered; Figure 4.1b). 
The red colour of the recovered 'purified' DNA from the RCC sample also indicated 
that this was significantly contaminated with haemoglobin (not shown). Repeated 
attempts to modify this method resulted in the same unsatisfactory results with 
spiked RCCs. 
4.2.3 A novel rapid method for the extraction of DNA from bacteria in blood 
products 
Although both Qiagen and the Bio101 kits met some our needs in terms of 
sample types and speed, neither was capable of extracting DNA from all bacteria and 
all blood products from a 1000 !IL starting volume. Therefore, bead beating (for 
effective and rapid disruption of Gram-positive species, without the incubation 
period needed for enzymatic lysis) and spin column cleanup were combined. To 
process a 1000 i.t,L sample, we added a pre-bead beating lysis step to remove the bulk 
of the cells from each blood product, particularly the RCCs. 
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The detailed protocol is provided in Chapter 2, Section 2.6.3. Briefly, up to a 
50 !IL pellet of washed bacteria, or a 1000 lit sample of spiked blood product was 
treated with pre-lysis buffer, mixed, and the debris was pelleted by centrifugation. 
After removal of the supernatant, the pellet was resuspended in the bead-beating lysis 
buffers, and treated in the FastPrep machine for 3 min on speed 5.5 to ensure 
maximum bacterial lysis. Potassium acetate was added to the recovered supernatant 
to precipitate protein in the sample, followed by Proteinase K treatment for any 
remaining protein. From this step, the Qiagen method of spin columns and wash 
buffers was used to clean up the samples and precipitate the DNA, prior to storage at 
4°C in Buffer AE. Samples of our DNA extracts from 100 fig of washed bacterial 
cells (10 p.L of 100 p,L of total purified template, giving 200 pg/uL template) were 
examined by electrophoresis, and are shown in Figure 4.2. This extraction technique 
was highly successful with the target of 1000 p,L of spiked blood product, and with 
all species of bacteria (>30) tested (results not shown). Some samples contained 
residual RNA, which was removed (when desired) by treatment with RNase. 
Although some shearing of the template was evident by smearing of samples 
on gel electrophoresis, the majority of the sample appeared to be intact. To confirm 
the intactness of the template and minimise the risk of false-negatives (which would 
occur if the only intact template were smaller than our target), sterile PC and RCC 
controls were extracted and subjected to PCR for the p-globin gene using a range of 
primers for different length targets (Figure 4.3). All primer pairs produced 
amplicons, including the largest target of almost 1500 bp. These results showed that 
our template is both sufficiently intact and free from reaction inhibitors (such as 
haeme) and indicated that false negative reactions are unlikely to occur. 
Having developed a method to obtain PCR quality DNA, we investigated various 









Figure 4.2: Extraction of DNA washed bacterial cells, 
using the developed novel rapid method of bead beating 
with spin column purification 

























Figure 4.3: 13-globin PCR demonstrating intactness and 
purity of DNA extracted from sterile PCs by 
our novel rapid method 
NTC; no template control. 
4.3 Detection of bacterial contaminants using PCR 
As stated earlier, our ultimate goal was to use conserved 16S sequences to 
detect all bacterial contaminants in a single reaction. However, many factors may 
influence the ability to detect a target in any given sample. For a PCR reaction to be 
positive, the selected primers must be able to bind the target sequence, and the Taq 
polymerase must be able to use these to produce multiple copies. The presence of 
inhibitors (through poor template preparation), incorrect cycling conditions or design 
of the primers, may lead to false-negative results. These issues also apply to 16S 
universal PCR, but in addition, false-positive results may occur in sterile samples, 
due to the ubiquitous nature of the 16S template in the environment, and the 
conserved sequences which are being targeted (163). As indicated in Section 4.2.3, 
the template obtained was of PCR quality, but in order to address these other issues 
adequately and ensure no loss of specificity or sensitivity with universal PCR as 
compared to species-specific targeting, the approach adopted was: to sequentially 
detect S. aureus and Y. enterocolitica at the species, genus, Gram, and universal 
levels. 
4.3.1 Bottom-up detection of S. aureus and Y. enterocolitica: species 
specific to universal 16S PCR 
Figure 4.4 shows the genetic targets and the desired levels for testing the PCR 
process with our samples. These were selected as a majority of these assays were 
available from published methods. Comparisons of both standard and real-time PCR 
methodologies were adopted to ascertain which might be more suitable, as each has 
particular advantages (discussed in Chapter 1, Sections 1.8.1 and 1.8.2). The same 
gene targets were used for both methodologies. 
4.3.2 Standard PCR amplification 
Standard PCR amplification requires DNA polymerase and specific primers 
to manufacture many copies of a target which may be up to 30 kb or more in length, 
depending on the enzyme used. Post-cycling, samples are subjected to gel 
electrophoresis, where a presumptive identification of a positive reaction is made, 
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Species level 
(Y. enterocolitica [ail] and S. aureus[mecA]) 
Genus level 
(Yersinia[ymoA] and Staphylococcus [tut]) 
Gram-positive or Gram-negative 
(semi-universal PCR [16S]) 
Jo_ 
16S ribosomal RNA 
(universal PCR [16S]) 
Figure 4.4: Strategy used to develop a method to detect 
bacteria using 16S universal PCR 
based on the size of the amplified fragment. However, absolute confirmation of the 
identity of the PCR product must be made through sequencing or probing with 
known sequences (such as Southern dot blotting, discussed in Section 4.4.2). 
4.3.2.1 Species-specific targets — S. aureus mecA and Y. enterocolitica all 
genes 
Our selected targets for species-specific identification of S. aureus and 
Y. enterocolitica, were mecA and all, respectively, which have been successfully 
used with a variety of sample types such as milk and food (15, 208). A 10 pL 
volume of template was used in each reaction, as this was shown to increase the 
sensitivity of these PCRs. Typical results for the S. aureus mecA and 
Y. enterocolitica all PCRs are shown in Figures 4.5a and 4.5b, respectively. A 
summary of the sensitivities achieved for these PCRs along with PBS, PCs, and 
RCCs spiked with bacteria and for DNA template, is shown in Table 4.1. As little as 
15 fg (1 genome) was detectable for Y. enterocolitica, whilst for S. aureus the 
smallest detectable amount was 143 fg of DNA (-80 genomes). Fewer than 30 
bacteria in a sample could be detected from our spiked extracts. Importantly, 
although some difference in sensitivity was observed based on the source of the 
template (whether it was from bacteria spiked into PBS or blood products) it did not 
rise above the set limit of 103 CRI/mL. Sequencing of randomly selected samples 
showed that the correct target had been amplified in each instance. Non-target 
species did not produce amplicons, nor did the sterile no template controls (NTCs). 
Having shown that detection at this level can be reliably achieved within our 
specificity and sensitivity requirements, we examined whether the same could be 
achieved at the genus level. 
4.3.2.2 Genus-specific targets — Staphylococcus tuf and 
Yersinia ymoA genes 
For genus-specific detection of Staphylococcus and Yersinia spp., the tuf and ymoA 
genes, respectively, were amplified using published primers and methods (85, 127). 
Again, 10 p,L of template was used in each reaction. Typical results for these are 
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Figure 4.5: Representative species-specific standard PCR results 
a) mecA - S. aureus in PBS. Pure S. aureus DNA was used as a positive control, 
whilst P. aeruginosa was a negative control. NTC; no template control. 
b) all - Y. enterocolitica in PBS. Pure Y. enterocolitica DNA was used as a 
positive control, whilst P. aeruginosa was a negative control. 
Details of the primers and conditions can be found in Chapter 2, Section 2.8.2.3 
and Table 2.3. 
Table 4.1: Comparative sensitivities of species-specific PCRs 
Data are the mean of two separate experiments. PCR samples were 
conducted in duplicate. 
CFU/mL 
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Figure 4.6: Representative Yersinia and Staphylococcus genus-
specific standard PCR results 
The source of DNA is shown above each lane. 
a) tuf - S. aureus in PBS. Pure S. aureus DNA was used as a positive control, 
whilst P. aeruginosa was a negative control. NTC; no template control. 
b) ymoA — Y. enterocolitica in PBS. Pure Y. enterocolitica DNA was used as a 
positive control, whilst P. aeruginosa was a negative control. 
Details of the primers and conditions can be found in Chapter 2, Section 2.8.2.4 






A summary of the sensitivities achieved for these targets is shown in Table 4.2. 
Although the sensitivity appeared to be lower compared with the species-specific 
PCRs, the numbers of CFU/mL that were detectable were similar. The source of the 
template did not affect the sensitivity of the assay, and in each PCR, only members 
of the relevant genus produced amplicons of the expected size (Table 4.3). Random 
sequencing of these indicated that the intended target had been amplified in each 
instance. The NTCs were negative as expected. 
As we had shown that PCR was successful using our template, without 
evidence of inhibition, or the template being overly sheared, we shifted our study to 
an investigation of 16S protocols. A semi-universal 16S PCR (Gram-positive or 
Gram-negative only) was evaluated initially; then a universal PCR to detect all 
bacterial species. 
4.3.2.3 Semi-universal 16S PCR — Gram-positive only or Gram-negative 
only 
As with the species- and genus-specific PCRs, the method and primers for the 
semi-universal detection of Gram-negative or Gram-positive species were obtained 
from published sources (88, 114). Both assays were targeted at a 313 bp region of 
the 16S gene. The Gram-positive PCR (Figure 4.7) successfully amplified all but 
one appropriate target (that being Corynebacterium sp., Table 4.4), without any false 
positive results from Gram-negative bacteria. However, many Gram-negative 
species failed to be identified by the Gram-negative PCR, and non-specific products 
of an unexpected size (indicated by white arrow in Figure 4.8) were present in some 
samples that contained Gram-positive template. Despite attempts to optimise the 
PCR by varying the primer, MgC12 concentrations the cycling conditions, it remained 
unreliable. Furthermore, as the Gram-specific PCRs utilised a small region of the 
16S sequence, both produced occasional false positives (of the expected 300 bp size) 
in their NTCs (not shown). 
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Table 4.2: Sensitivities of Yersinia and Staphylococcus 
genus-wide PCRs 
CFU/mL 











Table 4.3: Specificities of Yersinia and Staphylococcus 
genus-wide PCRs 
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Figure 4.7: Representative results of generic PCR for Gram-
positive bacteria 
NTC; no template control. 
Details of the primers and conditions can be found in Chapter 2, 
Section 2.8.2.5 and Table 2.3. 
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500 313 bp 
Figure 4.8: Representative results of generic PCR for Gram-
negative bacteria 
Unidentified non-specific amplicon indicated by white  arrow. 
The source of DNA is shown above each lane. NTC;  no template 
control. 
Details of the primers and conditions can be found in Chapter 2, Section 
2.8.2.5 and Table 2.3. 
Treatment of the PCR mastermixes with ultraviolet (UV) light prior to the addition 
of template (180) did not resolve this issue, nor did the strict control and replacement 
of reagents. Other published primer pairs and conditions were investigated (43) for 
detection of Gram-negative bacteria, but all produced similar or even less 
satisfactory results (not shown). For these reasons, we chose not to continue to our 
Gram-specific PCR experiments (in standard or real-time formats), but pursued a 
universal 16S PCR, instead. 
4.3.2.4 Universal 16S targets — conserved 16S DNA regions possessed by 
all bacteria 
Initially, our universal 16S PCR utilised published primers and targeted a 333 
bp region of the gene (114). The PCR successfully amplified all 47 species and 
strains tested using 10 p,L of template, showing it was capable of the universal 
targeting we had envisaged (Figure 4.9a). However, despite strict reagent handling 
measures and UV treatment of plasticware and the mastermix, false-positive 
reactions were a frequent occurrence (Figure 4.9b), and were observed in our NTCs 
and sterile PC and RCC extracts. We hypothesised that contaminating DNA was 
influencing these PCRs and producing false positive results, and that contamination 
of thus type could cause similar problems if this PCR was adopted by the transfusion 
industry. 
Accordingly, we decided to target a larger fragment of the 16S gene (over 
1000 bp), as many sources had reported that PCRs with amplicons of this size were 
significantly less vulnerable to producing false-positive results. The method and 
primers of Lane (1991) targeted a 1361 bp section of the 16S gene, and like our 
smaller fragment universal PCR, successfully amplified all 47 species and strains 
tested (Figure 4.10). Unlike the smaller universal PCR, however, no false-positive 
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Figure 4.9: Representative results of universal 16S 333 bp 
PCR for bacteria 
The source of DNA is shown above each lane. 
a) correctly amplified products. NTC; no template control. 
b) showing false-positive results from sterile PC, RCC, and NTC. 
Details of the primers and conditions can be found in Chapter 2, 





Figure 4.10: Representative results of 16S universal 
1361 bp PCR 
The source of DNA is shown above each lane. 
NTC; no template control. 
Details of the primers and conditions can be found in 
Chapter 2, Section 2.8.2.7 and Table 2.3. 
Moreover, the sensitivity of each PCR was comparable to the species- and genus-
specific PCRs, and was not influenced by the type of sample (Table 4.5). Random 
sequencing showed that the 16S gene had been amplified in each instance, giving the 
signature sequence of the expected bacterium (Table 4.6). 
On the basis of these results this approach was adopted as the mainstay of the 
final screening method (a complete account of which is detailed in Chapter 5). 
However, investigations into the possibility of using real-time PCR were continued, 
because of its advantages in terms of speed and potential for automation. 
4.3.3 Real-time PCR amplification 
Like standard PCR, real-time PCR involves the use of primers and Taq 
polymerase to manufacture many copies of a target gene. Yet, unlike standard PCR, 
real-time PCR can be conducted in less than an hour due to the small (typically less 
than 200 bp) size of the target. Post-reaction electrophoresis is also unnecessary, 
because the reporting is conducted in 'real time' during the PCR, by fluorescent dyes 
such as SYBR green or fluorescently-labelled oligoprobes. As several PCRs were to 
developed, SYBR green was selected as the reporting tool, as this can be used for all 
reactions, and is not dependent on sequence-specificity as with the labelled 
oligoprobes. SYBR green operates by interchelating any double stranded DNA, so 
that as the amount of amplicon increases so does the fluorescent signal. Samples that 
do not produce amplicons do not fluoresce. When SYBR green is used as the 
reporter, presumptive identification of the product can be made post-cycling by a 
melt profile. The temperature of each sample is raised by 1°C increments, and as the 
amplicon melts, the SYBR green fluorescent signal is extinguished. As each 
sequence produces a signature melt profile, these allow for the presumptive 
identification of an amplicon (in the same way that the migration of an amplicon on 
gel electrophoresis post-standard PCR allows for presumptive identification of that 





Correct sequence Incorrect sequence 
Table 4.5: Sensitivity of universal 1361 bp 16S PCR for 
bacterial targets 
CFU/mL 











Table 4.6: Specificity of universal 1361 bp 16S PCR for 
bacterial targets 
NB: Sterile blood product extracts and NTCs were negative as expected. 
4.3.3.1 Universal 16S targets — conserved 16S DNA regions possessed by 
all bacteria 
The method of Nadkarni (143) was used to detect a 466 bp region of the 16S 
gene (Section 2.8.3.3). In their procedure, a 16S Taqman probe was used to confirm 
the amplicon was from a bacterial source. As the eventual goal was to individually 
identify the bacterial species in the PCR, we chose SYBR green as our reporter (with 
a view to develop the specific probes at a later stage, after showing the 16S real-time 
PCR was viable). Nadkarni used a commercially available mastermix, but a lab-
made mix was initially used for these preliminary investigations. To ensure that an 
amplicon was produced, we first conducted trials using standard PCR and gel 
electrophoresis. Parallel assays were run, one of which contained SYBR green, and 
the other which did not. This was necessary to optimise the concentration of SYBR 
green needed for each reaction, since it is capable of binding the double-stranded 
template and inhibiting the reaction. At the manufacturer's recommended SYBR 
green concentration, no inhibition of the PCR process was noted. However, despite 
UV treatment of the mastermix, false-positive results were consistently detected from 
our NTCs (Figure 4.11a). This could not be resolved, despite implementing 
extended (1 min) UV treatment of our mixes and ensuring fastidious handling and 
preparation of the samples. 
As an alternative, a commercially available mastermix was obtained from 
Invitrogen and the experiment was repeated with greater success. Three microlitres 
of template was used in each reaction, as greater amounts reduced the overall amount 
of amplicon produced, and also delayed the take-off point for the reaction by a 
number of cycles (not shown). Positive reactions were noted only when bacterial 
template was added to the mastermix and these were obtained for both trial species, 
S. aureus and Y. enterocolitica (Figure 4.11b). Figure 4.12 shows an example of the 
raw fluorescence, quantification, and melt profiles for a wide range of bacteria, using 
this PCR. All samples containing bacterial template were considered positive 
between 15 and 20 cycles of the program. All 12 species of bacteria tested were 
amplified by this method, with each producing slightly different melt profiles, due to 

















Figure 4.11: 16S Universal real-time PCR trial on 
standard equipment 
The source of DNA is shown above each lane. NTC; 
no template control. 
a) Home-made mastermix. 
b) Invitrogen mastermix. 
Details of the primers and conditions can be found 
in 












Figure 4.12: Representative real-time universal 16S FOR of 
a range of species 
a) raw fluorescence of samples. 
b) quantification (when samples become positive). 
c) melt profile. dF/dT; differential (when amplicon dissociates). 











However, this success could not be repeated with spiked PCs and RCCs which 
frequently gave a signal in the NTCs (not shown). 
These experiments have shown that detection of bacterial DNA using real-time 
PCR and conserved 16S universal sequences in blood products may not be reliable, 
and that the method requires significant further optimisation. The success of 1.4 kb 
16S PCR using standard equipment encouraged us towards investigating this 
technique thoroughly in order to achieve the aims of the project. 
4.4 Confirmation and identification of bacteria post PCR 
Once the ability to detect bacterial contaminants using standard 16S universal 
PCR in a sensitive, specific and timely manner was in place, it was important to 
confirm that the products detected were in fact 16S amplicons, and to determine if 
they could be used to identify the species of the bacterial contaminant. 
Confirmation of PCR products may be achieved by several techniques. 
Sequencing of the 16S gene is commonly used when identifying unculturable 
bacteria. However, sequencing is expensive and impractical for the number of 
samples that would need to be processed for blood product screening. Instead we 
decided to confirm and identify these PCR products using oligonucleotide probes 
targeted to the variable regions of the 16S gene, and compare the efficacy of PCR-
ELISA and Southern dot blotting for this purpose. 
4.4.1 PCR-ELISA 
Provided as a kit, PCR-ELISA uses biotinylated oligonucleotide probes to 
hybridise to DIG-labelled PCR products, with the hybrids detected by using an anti-
DIG antibody and peroxidase colour reaction. The assays are carried out in 
streptavidin-coated 96-well ELISA trays, with the oligoprobes capturing the samples 
in the wells. This allows testing of many probes simultaneously, in a macroarray 
arrangement. PCR-ELISA has been used previously to detect viral, bacterial, and 
eukaryotic DNA, from a range of sample types such as food, serum, and tissue 
biopsies (184, 198, 228). The oligoprobes selected were of similar melting 
temperatures, with the aim that all might be used simultaneously. An example of the 





















Figure 4.13: DIG-labelling by PCR of 16S product for 
detection by PCR-ELISA 
The source of DNA is shown above each lane. 
a)Unlabelled PCR product. 
b)DIG-labelled PCR product. 
A graph of typical results (averaged from duplicate samples) using the PCR-ELISA 
is shown in Figure 4.14a. 
It was apparent that despite strict adherence to the assay protocol, there was 
considerable non-specific binding of the anti-DIG antibody to samples that did not 
contain DIG-labelled PCR product. After investigating the available literature, a 
blocking step using a PBS/skim milk buffer was implemented prior to applying the 
anti-DIG antibody to the samples. This approach significantly reduced the 
background (Figure 4.14b), but the strength of positive signals was not of the same 
order as those obtained when using the DIG-labelled PCR and the probe supplied 
with the kit. Despite many attempts to optimise this method by varying the 
annealing temperature of the assay and using a range of probes, detection could not 
be improved. Furthermore, repeat assays under identical conditions produced 
variable results (Figure 4.15), and it became apparent that this method was not 
consistent or reproducible. Therefore, Southern dot blotting was investigated as an 
alternative detection method. 
4.4.2 Southern dot blot 
Southern dot blotting is a technique by which sequences can be identified 
through hybridisation with a probe of a known sequence. It can be performed in two 
orientations: with the DIG-labelled probes of known sequence in solution, and the 
unidentified sample bound to a membrane (standard orientation), or whereby the 
DIG-labelled samples are in solution, with the probes of known sequence bound to 
the membrane. Each technique has advantages and disadvantages compared with the 
other. The standard orientation allows for many samples to be examined with a 
single probe, whilst reverse-probing allows a single sample to be tested against many 
probes simultaneously (similar to the PCR-ELISA approach). The aim was to 





S. aureus P. aeruginosa 	Strep. 
pneumoniae 
• 1 in 10 dil 
• 1 in 100 dd 
ono DIG PCR prod 
E no biotin oligoprobe 
group B 	S. aureus 	P. aeruginosa 	Strep. 	Kit control 
streptococcus pneumoniae 
Figure 4.14: Example data obtained by PCR-ELISA detection 
of DIG-labelled 16S PCR products 
a) standard kit protocol. 
b) modified blocking protocol 
dil; dilution of DIG-labelled 16S PCR product. NTC; no template 
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Experiment 1 Experiment 2 	 Experiment 3 
Figure 4.15: Detection of B.cereus by PCR-ELISA — variability 
between experiments 
Note: same conditions, DIG-labelled PCR product and, amount of 
oligoprobe used in all experiments. dil; dilution of DIG-labelled 16S PCR 
product. NTC; no template control. All results are the average of 
duplicate wells. 
4.4.2.1 	Reverse dot blot 
We have already shown that conserved bacterial 16S sequences from a 
diverse range of species can be amplified from pure cultures and spiked blood 
products with a high degree of specificity and sensitivity. Oligonucleotides were 
selected as probes, as these are able to differentially target the unique and variable 
16S sequences more specifically than larger probes. Instead of designing these 
probes to be of similar annealing temperatures, we selected or designed them to be 
18-mer lengths, and to use buffers containing the quaternary ammonium salt 
tetramethylammoniumchloride (TMAC) to stabilise the A-T, and G-C bonds to be of 
equal melting temperature (Tm). These buffers allow hybridisation of the target and 
probe to occur strictly by sequence matching (102, 130, 222). The probes were 
spotted onto a positively charged nylon membrane at a range of concentrations, as 
were unlabelled positive and negative control PCR products. Hybridisation of the 
DIG-labelled PCR product to the membrane-bound probes was optimised over a 
range of temperatures (40 to 60°C), but none produced positive signals except where 
the DIG-labelled PCR product had bound to its unlabelled equivalent (an example of 
which is shown in Figure 4.16a). Furthermore, hybridisation temperatures below 
50°C yielded non-specific interactions (and hence false-positive results) between 
sterile RCC extracts and the anti-DIG antibody (Figure 4.16b). We examined the 
need for purification of these PCR products generated from RCC extracts with the 
QIAquick PCR purification kit, but found this step was unnecessary and that 
hybridisations and washes conducted at 50°C were sufficient to prevent non-specific 
interactions. 
To determine if the oligoprobes were bound to the membrane throughout 
probing and detection at this temperature, some probes were DIG-tailed, applied to 
the membrane and detected directly. Figure 4.16c shows an example of the probes 
stably bound and detected at this temperature. Some investigations have utilised 
poly dT tailing with short oligoprobes (such as those used here) to enhance their 
binding efficiency (107, 178, 229). This technique was successfully applied to the 
S. aureus-specific probe (Saur2) for 1 h (not shown), but this made no difference to 














group A streptococcus 
16S PCR product 
S. aureus 
	16S PCR product 
RCC PC Spv2 
Spy2 
DIG-tailed Spy2 
Figure 4.16: Representative reverse dot blots of 1361 bp 
PCR product 
a) Hybridisation at 55°C of group A streptococcus specific 
probe (Spy2). 
b) non-specific binding of sterile RCC extract to anti-DIG 
antibody at 55°. 
c) oligoprobes remain bound to membrane throughout probing, 










Figure 4.17: Effect of poly dT tailing of on the ability to detect 
S. aureus using a S. aureus-specific probe 
Reverse dot blot of membrane bound poly dT tailed and untailed 
Saur2 probe and 16S PCR product to DIG-labelled S. aureus 16S 
product 
All samples spotted in duplicate. 
A range of tail lengths were then explored to determine if another would be suitable. 
In addition, DIG-labelled PCR samples were digested with Rsal, in the event that the 
1400 bp product was too large for an 18-mer probe to bind, or if the homologous 
binding site was masked by the tertiary structure of the 16S molecule. Although 
complete cleaving of the PCR product was achieved (not shown), this still did not 
allow successful hybridisation, nor did the range of dT tail lengths have any effect 
(Figure 4.18). 
Results thus far using reverse dot blot did not suggest this technique was 
going to be successful in this instance, so the standard orientation was investigated 
instead. 
4.4.2.2 Standard dot blot 
As the reverse dot blotting experiments showed a tendency for non-specific 
interactions to occur between sterile RCC extracts and the anti-DIG-antibody at 
hybridisation temperatures below 50°C, probes were selected or designed to 
hybridise at this temperature. For standard dot blotting, the oligoprobes were DIG-
tailed and diluted to the recommended concentration in DIG Easy-Hyb buffer. A 
range of 16S universal PCR products from different species was spotted onto the 
membrane, and allowed to hybridise with the DIG-labelled oligoprobes. Detection 
of the probe-PCR hybrids was successful at the first attempt, and no false-positives 
were detected in sterile blood product extracts (Fig 4.19). The sensitivity of 
detection was reliant upon the initial generation of the PCR product. Therefore, the 
sensitivities of the standard dot blots were the same as those for the PCR itself (Table 
4.5). Despite careful design of each probe, some resulted in non-specific 
hybridisation (Figure 4.20a), as could be expected from targeting a 16S sequence 
which contains many shared sequences between species. However, careful re-
designing of the probes allowed the desired result to be obtained (Figure 4.20b). 
The success achieved by the standard dot-blotting procedure provided us with 
a mechanism for detecting and identifying bacterial contaminants in blood products. 
This technique was, therefore, selected for further investigation, as described in 
Chapter 5. 
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no tail 100 pM 
no tail 50 pM 
60 min dT tail 
20 pM 
30 min dT tail 
20 pM 
15 min dT tail 
20 pM 
S. aureus 16S PCR 
product 
Figure 4.18: Reverse dot blot of Rsal digested, DIG-labelled 
S.aureus 16S PCR product, with the oligoprobe 
Saur2 poly dT tailed at a range of lengths 
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Figure 4.19: Representative standard dot blot of Strep. mitis 
16S PCR product with the probe STREP16SR 
All samples spotted in duplicate. 
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Figure 4.20: Representative standard dot blots of the 
Staphylococcus genus probe Staph3 
a) Staph1 probe showing non-specific detection of B. cereus 
b) Staph3 probe (redesigned from Staph1) showing detection of the 
staphylococci only 
All samples spotted in duplicate. 
4.5 Discussion 
With the continuing threat of bacterial contamination of the blood supply, and 
the absence of feasible measures to detect and prevent the administration of many of 
these contaminated products, the aim of this study was to develop means by which 
all bacterial contaminants could be detected and identified in blood products. A 
number of studies have shown that PCR of 16S sequences can be used to detect 
bacteria in clinical and environmental samples (143, 162), and this study has shown 
that it is also possible to detect a broad variety of contaminants in blood products, in 
the same way. Furthermore, contamination can be detected before the numbers of 
bacteria reach what are considered to be clinically relevant numbers, and before non-
invasive methods such as visual inspection for spoilage of the product can detect 
them. For efficient and rapid extraction of our samples we developed a novel 
method, as commercially available kits could provide the required speed or use the 
required sample volume. Confirmation of true positives and identification of the 
contaminant(s) responsible was achieved by Southern dot blot analysis with an array 
of specialised oligoprobes. This complete technique may prove useful in a range of 
clinical and diagnostic settings, apart from the screening of blood products. 
The foundation for the ability to detect bacterial contamination in blood 
products containing less than 10 3 CFU/mL rested with the ability to extract DNA 
from each of the diverse array of bacteria typically found in PCs and RCCs quickly, 
efficiently, and cleanly, without introducing extraneous contaminants. Extraction 
kits are at the forefront of molecular clinical diagnoses, due to their simplicity and 
consistent results and were, therefore, our first choice for examination. However, 
neither of the kits trialled could process our target volume of 1000 l.LL, nor were they 
able to remove enough of the considerable particulate matter from RCC samples. A 
prelysis, step such as that used in our method, may provide an opportunity for 
processing of larger samples and a greater ability to remove cellular debris prior to 
the extraction process itself. However, the reliance of the Qiagen kit upon the 
enzymatic lysis of bacteria would still make this method too slow for this 
application. A bead-milling process similar to that used by BI0101 is available from 
Qiagen, and would be worthy of investigation in the future. The novel extraction 
method developed in this Chapter combining bead-milling and spin column cleanup, 
116 
provided a sample suitable for analysis in under 2 hours. Although some template 
shearing occurred due to the nature of the milling process, this had no effect on the 
ability to amplify targets of up to 1.5 kb, with a sensitivity within our cut-off of 10 3 
CFU/mL. Furthermore, the DNA purified by this method could be used in several 
downstream applications such as PCR (both standard and real-time) and Southern dot 
blot. Further investigations are currently underway to apply this method to a greater 
range of sample types (e.g. tissue) and bacterial species (e.g. Mycobacterium spp.), 
and to expand the range of applications to which the purified template can be 
applied, such as DNA cloning. Other advantages of this method are that it requires 
no hazardous phenol/chloroform, and that many samples can be processed 
simultaneously. The rate-limiting step of the procedure is the Proteinase K treatment 
which requires 1 h incubation. Further optimisation of this method should include 
investigating the possibility of shorter incubation times, or alternative methods to 
reduce the protein content of samples. 
Diagnostic laboratories have increasingly adopted PCR to detect the cause of 
disease in a variety of circumstances (60, 126, 176). PCR has been particularly 
helpful in identifying pathogens and environmental commensals, where traditional 
methods such as culture have failed. Numerous recent publications have explored 
the use of conserved bacterial 16S sequences to detect bacteria from a variety of 
sources, although none has applied this technology to bacteria in blood products. 
Template produced by the novel method presented here could be used in PCR for 
targets of at least 1.5 kb, and allowed specific and sensitive detection of less than 100 
bacteria from pure cultures and each of the blood product types tested. Furthermore, 
the sensitivity was approximately the same for both standard and real-time PCR, 
despite the differences in the amount of template used, and the way in which a 
positive result was identified. 
As previously reported, the success of universal 16S PCR is determined by 
the size of the target. Numerous publications have highlighted the issue of 
contaminating environmental DNA, and its propensity to give false-positive results 
where small PCR targets are used (163). The source of such contamination can be 
from any of the reagents used in the extraction or the PCR process, or it can surface 
from the samples themselves, which may be sterile but contain bacterial DNA (129). 
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Fastidious handling of reagents and samples (as in this study) is not always fail-safe, 
nor is the UV treatment (to crosslink any endogenous contaminating nucleic acid) of 
plasticware and reagents prior to the addition of template. Some investigators have 
advocated treating the PCR mastermixes with restriction enzymes or DNases (42, 54, 
185). However, as these enzymes are from bacterial sources (and hence may contain 
bacterial DNA), they can exacerbate the problem of false-positive reactions (94). 
We found that the use of commercially available PCR mastermixes reduced (but did 
not eliminate) the incidence of false-positives during real-time PCR. These may also 
be useful in standard PCR. The future availability of 'DNA-free' plasticware and 
reagents should also have a positive effect on the ability to perform smaller fragment 
16S PCR. In this study, however, the most successful approach to eliminating the 
problem of false-positives during universal PCR was to target a large (1.4 kb) region 
of the 16S gene. The basis for the success of this method is that most environmental 
DNA is much smaller than this target size and therefore cannot be amplified. Studies 
of bacteria spiked into blood products showed that this PCR was able to reliably and 
detect all of the diverse species of bacteria tested by this assay with a sensitivity 
below the target of 103 CFUhnL. 
Following the successful universal amplification of bacterial DNA, the next 
task was to confirm the positive PCR reactions and identify the bacterium 
responsible. Several techniques were compared, the most successful of which was 
Southern dot blotting with labelled oligoprobes. 
Although PCR-ELISA has previously been used to detect a range of 
infectious agents from clinical and food samples (184, 198, 228), in this instance the 
oligoprobes failed to hybridise with the target PCR product, despite many attempts to 
optimise the method. This may have been due to an incompatibility in probing a 
1361 bp sequence, with a 20-mer probe. Generally, published probes used in PCR-
ELISA are between 10 and 20% of the length of the sequence they are targeting, 
which would suggest that in order to detect our large PCR product, a probe of at least 
140 bp would be required. The alternative approach (i.e. generating a smaller PCR 
product in order to use these existing probes), was not feasible, as PCRs which 
generate low molecular weight products tend to give false-positive results, such as 
occurred with the 300 bp universal PCR trialled in this study. Furthermore, DIG- 
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selected genera, the family Enteribacteriaceae, Gram positive or Gram-negative 
species, or all species, with a universal 16S probe (details of which are provided in 
Chapter 5). 
In summary, sample extraction using a bead-beating, deproteination and spin 
column purification followed by large-fragment 16S universal PCR, and standard 
Southern dot blotting was the most successful method for detecting contamination in 
blood products. The preliminary success with this method laid the basis for further 
investigations with a large range of bacteria, further probe development, and 





BACTERIAL CONTAMINANTS IN 
BLOOD PRODUCTS USING 
UNIVERSAL 16S PCR AND 
SOUTHERN BLOT 
5.1 	Introduction 
We have shown that it is feasible to use 16S universal PCR and Southern dot 
blot to identify contaminated products specifically and sensitively, whilst confirming 
the positive result and identifying the contaminant. Therefore, it was warranted that 
the repertoire of probes be expanded and tested on pure cultures, spiked PCs and 
RCCs. Further validation of the protocol with samples kept from the growth kinetic 
studies described in Chapter 3 was also desirable, to determine if this method 
performs differently with bacteria that have been allowed to proliferate in stored 
products over time. 
5.2 Selection, extraction, PCR and Southern dot blot detection of samples 
Initially, pure cultures and spiked blood products were used to evaluate the 
extraction, PCR and the Southern dot blotting processes. 
5.2.1 Selection of frozen, growth-kinetic samples for testing 
For the growth kinetic experiments (detailed in Chapter 3), the samples from 
the Y. enterocolitica PC and RCC experiments (starting spiking numbers of 10 1 and 
102 CFU/mL) were selected for study. The replicates from each day's sampling were 
pooled (i.e., the five 0 d samples were pooled together, the five 1 d samples, and so 
on), as we knew the number of CFU/mL in these. Following thorough mixing, 
1000 !IL aliquots were taken from each day's pooled samples and extracted using the 
novel developed method (Section 4.2.3), before elution into 100 lit AE buffer. 
5.2.2 Preparation of spiked PC and RCC samples for testing 
A range of bacterial species were spiked at a concentration of approximately 
109 CFU/mL into PC and RCC samples, and extracted by our novel rapid method. 
Spiking numbers were checked by plate count and were between 10 8 and 109 
CFU/mL. 
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5.2.3 PCR of samples 
Ten microlitre aliquots of template (extracted from frozen samples, spiked 
PCs and RCCs and pure cultures) were subjected to 50 cycles of the 1361 bp 16S 
universal PCR. Ten microlitre PCR samples were checked by gel electrophoresis for 
the presence of amplicons of the expected size. Half of each remaining RCC PCR 
sample was purified by the QIAquick PCR purification kit. 
5.2.4 Selection of oligoprobes 
Oligoprobes were selected according to their anticipated target. Some were 
from published sources, and others were designed in this study using the 
CLUSTALW and BLAST algorithms (Table 2.5). 
5.2.5 Southern dot blot detection of bacteria using oligoprobes 
The complete method is described in Chapter 2 (Section 2.11.3), but briefly, the 
oligoprobes were DIG-tailed and diluted in DIG Easy Hyb buffer, according to the 
manufacturer's recommendations. One microlitre aliquots of PCR product were 
spotted in duplicate onto nylon membrane, along with the appropriate negative 
(sterile PCs and RCCs) and positive (pure culture PCR product) controls. 
Hybridisation and stringency washes were conducted at 50°C, and detection was by 
CPD-Star chemiluminescence. 
5.3 	Southern dot blot of PCRs from pure cultures and spiked PCs and 
RCCs 
Of more than 50 probes investigated, 14 were found to be useful. 
5.3.1 SP16SR - 16S Universal probe 
First published by Hendolin (90), this generic 16S primer was found to be a 
useful universal probe, as it detected all bacterial species that it was tested against, 
and it did not cross-react with human DNA (from sterile PC and RCC extracts). The 
specificity of this probe was the same with all sample types (PCR products generated 
from pure cultures and spiked PCs and RCCs). An example blot and a summary of 
results obtained for this probe are presented in Figure 5.1. 
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Figure 5.1: SP16SR universal 16S probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
5.3.2 143+3 - Gram-positive probe 
The Gram-positive probe used in this study was based on an oligonucleotide 
used for PCR of Gram-positive species by Klausegger (114). The original published 
probe (143 , see Table 2.3) was trialed for use, but the positive signals (although 
correctly targeted) were weak (not shown). Several probes based on this sequence 
were designed, and probe 143+3 was selected as it gave strong positive signals with 
the presence of Gram-positive target, but not with non-targeted (Gram-negative and 
sterile PC and RCC controls) samples. The specificity of this probe was the same for 
all sample types, and an example blot and a summary of results for 143+3 are 
presented in Figure 5.2. 
5.3.3 Yent2/N6R - Gram-negative probe 
Several published Gram-negative probes were selected for study, the most 
successful of which was N6R (43), which reliably detected all Gram-negative 
species, except Y. enterocolitica (not shown). Several new probes were derived from 
this original sequence. However, these were also unable to detect Y enterocolitica, 
or gave rise to significant cross-reactions with Gram-positive species (not shown). It 
was then decided to combine equal quantities of N6R and Yent2 (which is a 
Y. enterocolitica-specific probe, discussed in Section 5.3.12) and apply this as the 
Gram-negative probe. This approach proved highly successful and detected all 
targeted species, without any non-specific activity, and regardless of sample type. 
This also showed that it was possible for several probes to be combined, rather than 
use a single probe for each blot. An example blot and a summary of results obtained 
for this probe are presented in Figure 5.3. 
5.3.4 Staph3 - Staphylococcus genus probe 
The Staph3 probe is novel to this study, and was produced using 
CLUSTALW alignments and BLASTN searches. Four novel probes were developed 
for investigation, but not all were found to be specific or as sensitive as intended (See 
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Figure 5.2: 143+3 Gram-positive probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
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Figure 5.3: Yent2/N6R Gram-negative probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
Staph3 gave strong positive signals for all three staphylococcal species tested, but not 
with other Gram-positive or Gram-negative species or sterile controls. An example 
blot and a summary of results obtained for this probe are presented in Table 5.4. 
5.3.5 Saur2 - S. aureus probe 
First published by Kempf (108), this probe proved highly sensitive and 
specific for its targeted species, S. aureus. It did not produce false-positives in the 
presence of other staphylococci, nor with any other bacterial species. Its specificity 
was consistent across all sample types. It did not cross-react with human DNA. 
Sterile PC and RCC controls were also negative. An example blot and a summary of 
results obtained for this probe are presented in Figure 5.5. 
5.3.6 STREP16SR - Strep. mitis/Strep. pneumoniae probe 
Conrads (52) designed this oligonucleotide to be able to detect all 
Streptococcus species when paired with a generic 16S partner. As a probe, it did not 
detect all Streptococcus spp. as hoped, although it did reliably determine the 
presence of Strep. mitis and Strep. pneumoniae DNA in samples. Since we were 
subsequently able to produce probes for the other streptococci of interest (Spy3 for 
group A and Saga for group B, described in Sections 5.3.7 and 5.3.8, respectively), 
we continued to test this probe for use as a dual species detector of Strep. mitis and 
Strep. pneumoniae. It was found to be highly reliable in the detection of both species 
in all samples types, without cross-reacting with non-target species or human DNA. 
PC and RCC controls were negative, as expected. An example blot and a summary 
of results obtained for this probe are presented in Figure 5.6. 
5.3.7 Spy3 - group A streptococcus probe 
The Spy3 probe used in this study was based upon the sequence of the Spy 
probe published by Trebesius (197). The original oligonucleotide sequence had a 
melting temperature (Tm) of just 48°C and was, therefore, unsuitable for use at our 
hybridisation temperature of 50°C. Several probes of different Tms were produced, 
and Spy3 was found to be reliable and specific, and did not cross-react with DNA 
from other bacterial species or with human DNA in sterile PC and RCC controls. 
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Figure 5.4: Staph3 Staphylococcus genus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
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Figure 5.5: Saur2 S. aureus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, 
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Figure 5.6: STREP16SR Strep. mitis/ Strep. pneumoniae 
probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
The sensitivity of probing was equivalent across all sample types, and an example 
blot and a summary of results obtained for Spy3 probe are presented in Figure 5.7. 
5.3.8 Saga - group B streptococcus probe 
The Saga probe (also from the laboratory of Trebesius (197)) proved to be 
specific in the detection of group A streptococcal DNA. This was despite the fact 
that its predicted Tm was just 2°C above the hybridisation and wash temperatures. It 
is recommended that all probes are 5 to 10°C above this. No cross-reactions with 
other DNA or false-positives in our sterile PC and RCC controls were seen, and the 
sensitivity was not influenced by sample type. An example blot and a summary of 
results obtained for this probe are presented in Figure 5.8. 
5.3.9 End 31 - Enterococcus genus probe 
Several putative Enterococcus genus probes were investigated. The most 
successful of these was Enc131 which was originally used by Behr (17) as a primer 
for an Enterococcus genus PCR. We found it was also highly suitable and specific 
with all sample types for Southern dot blot, and was able to detect both of our 
enterococcal test species (Enterococ. faecalis and Enterococ. faecium), without non-
specific detection of DNA from other species or the sterile PC and RCC controls. 
An example blot and a summary of results obtained for this probe are presented in 
Figure 5.9. 
5.3.10 Bcer1 - B. cereus probe 
Two B. cereus probes were designed for investigation and although both were 
successful in their targeting, Beer 1 produced the stronger positive signal, and 
consistently and specifically detected B. cereus DNA in all sample types. It did not 
react with non-target species. All controls were negative as expected. An example 
blot and a summary of results obtained for this probe are presented in Figure 5.10. 
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Figure 5.7: Spy3 group A streptococcus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, 
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Figure 5.8: Saga group B streptococcus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
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Figure 5.9: End 31 Enterococcus genus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
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Figure 5.10: Bcer B. cereus probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, 
negative result; NT, not tested). 
5.3.11 Entero1 - Enteribacteriaceae probe 
Probe D (published by Ootsubo) (150) was selected as the basis for the 
Enteribacteriaceae family investigations. As its Tm was just 43°C, it was redesigned 
into two new probes. However, neither of these was specific, and they detected both 
Gram-positive and Gram-negative species (not shown). Hence, a novel probe, 
Enterol was designed and successful in detecting all 8 species and strains of 
Enteribacteriaceae tested, in all sample types. This occurred without cross-reacting 
with the other Gram-positive or Gram-negative species tested. No false-positive 
results were seen from our sterile PC and RCC samples. An example blot and a 
summary of results obtained for this probe are presented in Figure 5.11. 
5.3.12 Yent2 - Y. enterocolitica probe 
After an unsuccessful trial of Yent 1 (Trebesius (196)), a novel probe, Yent2, 
was designed and tested for use against Y. enterocolitica. This was shown to be 
specific in detecting this species in each sample type, and did not produce false-
positives in the presence of human DNA or sterile PCs or RCCs. An example blot 
and a summary of results obtained for this probe are presented in Figure 5.12. 
5.3.13 Ppunew5 — Pseudomonas genus probe 
Ppunew5 was a novel probe designed to selectively detect P. aeruginosa and 
P. fluorescens. It successfully did this in all sample types, without false-positive 
reactions occurring. Human DNA and sterile PCs and RCCs were negative. An 
example blot and a summary of results obtained for this probe are presented in 
Figure 5.13. 
5.3.14 Paer1 — P. aeruginosa probe 
Initially, PsaerA was selected for study as a P. aeruginosa probe (96), and 
whilst this probe was able to selectively detect the target species, the positive signal 
was weak (not shown). A novel probe, Paer 1, showed equivalent specificity to the 
PsaerA probe, but gave a stronger signal in all sample types. This probe did not 
cross-react with any other bacterial species or human DNA. 
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Figure 5.11: Entero1 Enterobacteriaceae 16S probe results 
Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, 
negative result; NT, not tested). 
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Figure 5.12: Yent2 Y. enterocolitica probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, negative 
result; NT, not tested). 
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Figure 5.13: Ppunew5 Pseudomonas genus probe results 
a) Example blot with washed bacterial cells  for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe(+, positive result; -, negative 
result; NT, not tested). 
Sterile PC and RCC samples were negative as expected. An example blot and a 
summary of results obtained for this probe are presented in Figure 5.14. 
We had successfully designed or adapted an array of 14 probes, which were 
able to detect bacterial contamination specifically as designed, using PCR products 
amplified from pure culture, spiked PC or RCC templates. Frozen growth-kinetic 
samples from the experiments described in Chapter 3 were subsequently examined 
using the methods described in this Chapter, to further test the assay. 
5.4 Detection and identification of Y. enterocolitica from frozen samples of 
blood products using a novel extraction method, large-fragment 16S 
universal PCR, and Southern dot blot oligoprobing 
The aim of experiments described in this section was to determine whether 
the success of the extraction method, 16S PCR and Southern dot blot could be 
replicated with stored frozen samples from our growth kinetic studies. Since we 
knew the numbers of bacteria in each sample from plate counts conducted at the time 
of collection, we wanted to determine if we could amplify 16S products from these. 
As the bacteria had been allowed to grow in the blood products (rather than 
introduced at known concentrations using washed bacterial cultures), we also wanted 
to determine if the PCR process or detection was in any way influenced by these 
different sample types and whether the freezing and long-term (2 years) storage of 
samples had had any effect. We also wished to determine if the sensitivity of 
detection was at or below our target of 103 CFU/mL, and before product spoilage 
became evident, as was achieved with spiked products probing. 
Selection and preparation of our samples was undertaken as detailed in 
Section 5.2, and the extracts and PCR products were tested against each of our 
probes. 
5.4.1 Extraction of frozen PC and RCC samples 
Once thawed, the consistency of the PC and RCC samples was much more 
viscous than that of their non-frozen, spiked equivalents. Despite the use of 
anticoagulants when the sample was first collected, considerable clots were present 
in most samples (whether the product had spoiled during the kinetic experiments or 
not). We attempted to homogenise these by manual grinding. 
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Figure 5.14: Paer1 P. aeruginosa probe results 
a) Example blot with washed bacterial cells for PCR template. 
Duplicate dots. 
b) Table summary of accuracy of probe (+, positive result; -, 
negative result; NT, not tested). 
Processing of the 1000 1.1,L frozen samples was the same as for the extraction of the 
spiked product samples. 
5.4.2 1361 bp 16S universal PCR amplification 
PCR of samples was conducted in duplicate on two separate occasions. Ten 
microlitre samples were checked for the presence of amplicons, an example of which 
is shown in Figure 5.15. Generally, amplification was poor in samples containing 
103 to 107 CFU/mL, and was not evident in samples with fewer than 10 3 CFU/mL. 
The presence of protein in samples (in the form of a background smear) was also 
frequently noted. The samples obtained from the experiments (both PC and RCC) 
with a starting inoculum of 10 2 CFU/mL gave positive PCR results 1 to 2 samplings 
earlier than specimens inoculated with 10 1 CFU/mL. Amplification did not occur in 
our negative control PC and RCC extracts. 
5.4.3 Confirmation and identification by Southern dot blot 
One microlitre PCR samples were spotted in duplicate onto a membrane, and 
tested against our array of oligonucleotide probes. An example of this is shown in 
Figure 5.16. RCC samples that had been purified with the QIAquick PCR 
purification kit were spotted in parallel with non-purified samples, to determine 
whether this procedure had any effect on the outcome of the Southern dot blots 
(Figure 5.16b). The results for both starting inocula (10 1 and 102) were also 
compared for any apparent influence over the final result. 
5.4.3.1 Specificity of probes 
There were two overall groups of probes. One group, we expected to 
hybridise with Y. enterocolitica, while the other group was not expected to hybridise. 
The specificity of each probe was as found with pure cultures and spiked PCs and 
RCCs; with the universal 16S (SP16SR), Gram-negative (N6R/Yent2), 
Enteribacteriaceae (Enterol) and the Y. enterocolitica (Yent2) probes all hybridising 
with the Y. enterocolitica amplicon in all sample types, whilst the other probes did 
not. Subsequently, we divided the two groups of results into separate figures of 
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Figure 5.15: Representative16S universal 1361 bp standard  PCR 
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concentrates (10 1 CFU/mL inoculum) 
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Figure 5.16: Representative frozen blood product sample 
dot blot results — Yent2 probe 
a) PC sample extracts for PCR template 
b) RCC sample extracts for PCR template  (pre indicates samples not 
purified with QIAquick PCR purification kit;  post indicates samples 
have been purified with QIAQuick PCR purification kit) 
All samples were spotted in duplicate 
RCC 
Table 5.1a: Detection of Y. enterocolitica in frozen blood product samples from bacterial growth 
kinetic studies; targeted probes 
Probe 
Time- 
point SP16SR N6R/Yent2 Entero1 Yent2 CFU mL 
10 1 a 102 10 1 102 10 1 102 10 1 102 10 1 102 
0 d - 3.3x10 1 2 .3x 10 2 
1 d - - - 1.6x10 1 3.7x103 
2 d + + 3.4x103 3.5x107 
Ilh, + - 	+ 	 . 2.2x106 5.7x108 
4d 4.2x107 9.9x108 
5 d 3.6x108 1.8x109 
6d 1.3x109 2.2x109 







5.0x1Ou 2.3x10 1 
1 d 8.0x10° 4.0x10 1 
3d 2.0x102 1.1x103 
6d 2.3x10 5 2.3x105 
9 d 2.6x108 3.7x108 
12d 1.5x109 1.6x109 
15d 1.5x109 1.9x109 
18d 2.2x109 1.7x109 
21 d 2.6x109 1.7x109 
24d 1.9x109 2.2x109 
27d 2.2x109 2.4x109 
30d 1.6x109 2.2x109 
33d 2.3x109 2.6x109 
36 d 2.3X109 2.6X109 
a, size of original inoculum; +, positive result; -, negative result. Yellow shading indicates where QIAquick purified PCR product 
from RCC yielded + where previously -. Red shading indicates when spoilage of products became evident. 
Table 5.1b: Detection of Y. enterocolitica in frozen blood product samples from bacterial growth 
kinetic studies; non-targeted probes 
Probe 
Time- 
point 143+3 Staph3 Saur2 
Strep 
16SR Spy3 Saga Enc131 
Bcer1 Ppu new5 Paer1 CFU/ mL 
10' 102 10' 102 10' 102 10' 10 2 10' 10 2 10' 102 10' 102 10' 102 10' 102 10' 102 10' 102 
0 d - - - - - - - - - - - - - - - - - - - 3.3x10 1 2.3x102 
id - - - - - - - - - - - - - - - - - - - 1.6x10 1 3.7x103 
2d - - - - - - - - - - - - - - - - - - - - 3.4x103 3.5x107 
4d _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ - - 4.2x10 9.9x10 
5d - - - _ _ _ - _ _ _ _ - - - - - - - - - 3.6x10
8 1.8x109 
6d - - - - - - - - - - - - - - - - - - - 1.3x109 2.2x109 
7d - - - - - - - - - - - - - - - - - - - 1.5x109 2.4x109 
0 d - - - - - - - - - - - - - - - - - - - 5.0x10° 2.3x10 1 
1 d - - - - - - - - - - - - - - - - - - - 8.0x10° 4.0x10 1 
3d - - - - - - - - - - - - - - - - - - - 2.0x102 1.1x103 
6d - - - - - - - - - - - - - - - - - - - 2.3x105 2.3x105 
12d - - - - - - - - - - - - - - - - 1.5x10 . 1.6x10 
15d - - - - - - - - - - - - - - - - - - 1.5x109 1.9x109 
18d • • - - _ - - - - - - - - - - - - - - 2.2x109 1.7x109 
21d - - - - - - - - - - - - - - - - - - 2.6x109 1.7x109 
24d - - - - - - - - - - - - - - - - - - 1.9x109 2.2x109 
27d - - - _ _ _ _ _ _ _ _ _ _ - - _ - - 2.2x109 2.4x109 
30d - - - - - - - - - - - - - - - - - - - - 1.6x109 2.2x109 
33d - - - - - - - - - - - - - - - - 2.3x109 2.6x109 
36d - - - - - - - - - - - - - - - - - - 2.3x109 2.6x109 
a , size of original inoculum; *, non-specific detection; +, positive result; -, negative result. Red shading indicates when spoilage of products 
became evident. 
QIAquick PCR cleanup did not have a notable effect on the specificity of the probes, 
as no background interactions were observed in non-purified or sterile RCC samples 
(not shown). Whilst the results obtained were as expected, on one occasion, the 
Gram-positive probe (143+3) appeared to produce positive blots with the RCC 
extract PCRs (12 d to 36 d). However, repeated experiments with the same probe 
and samples did not produce this result again (not shown). The 12 d 10 1 RCC 
sample appeared to give a positive blot with the Spy3 probe, but as with the Gram-
positive probe, repeated experiments did not yield this result again. All negative 
controls (sterile PCs and RCCs) and positive controls (pure cultures of the 
appropriate species for the probe tested) gave the expected results. 
In summary, the specificity of each of the 14 probes tested against our frozen 
extracts was the same as obtained with pure cultures, and with spiked blood products. 
None of the Gram-positive or Pseudomonas probes were able to hybridise to the 
Y. enterocolitica PCR product, whilst the universal, Gram-negative, 
Enteribacteriaceae and Y. enterocolitica probes all did. 
5.4.3.2 Sensitivity of probes 
Whilst the specificity of the probes for DNA amplified from the frozen 
extracts mirrored the results obtained with pure cultures, and with spiked PCs and 
RCCs, the sensitivity of detection with the frozen samples was much less than that of 
other sample types tested. Positive signals were obtained in as little as 6 days post 
inoculation, but the number of CFU/mL in the frozen samples was 2 to 3 orders of 
magnitude greater than other sample types, and well above our targeted limit of 10 3 
CFU/mL. Although QIAquick PCR cleanup had no effect on the specificity of the 
Southern dot blots, it did produce some effect on the sensitivity, in that the purified 
RCC 10 1 samples gave positive signals up to 2 sampling time-points earlier than non-
purified specimens. However, this observation was not matched by the 10 2 samples. 
Generally, the sensitivity limitations were between 10 6 and 107 CFU/mL for PCs and 
105 and 108 CFU/mL for RCCs. Although this sensitivity was lower than we had 
anticipated, it may be explained and improved upon in the future in a number ways, 
as discussed in Section 5.5. 
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5.5 Discussion 
Due to the absence of practicable techniques to screen blood products for 
bacterial contamination, a range of molecular detection methods were examined. 
Large fragment 16S universal PCR has been applied to detect bacterial DNA in a 
range of environmental and clinical settings, and Southern dot blot is commonly used 
to identify specific sequences in DNA. However, neither of these had been applied 
together, to detect contaminating bacteria in blood products. When these techniques 
were combined, they were shown to be highly efficient at detecting bacteria in pure 
cultures and spiked blood products. Further probes were subsequently developed for 
this application. Once this method had been evaluated with pure cultures and spiked 
products, it was further tested on samples obtained from the growth kinetic studies 
(Chapter 3). This was necessary as bacteria that are allowed to proliferate within 
stored products may produce substances that could inhibit the detection processes. 
The extraction of the pure cultures and spiked PCs and RCCs was performed without 
difficulty, as per Chapter 4. However, the frozen samples from the kinetic studies 
were highly viscous, and many contained obvious clots. These were found in both 
spoiled and non-spoiled products (likely to be an artifact of prolonged storage), and 
were very difficult to disperse evenly throughout the sample prior to the removal of a 
1000 pi, aliquot for processing. As the lynchpin of the screening method, 
homogeneity of the sample is essential for the accurate and complete extraction of 
any bacterial DNA, and its subsequent detection. The viscosity and coagulation of 
these samples is likely to have influenced the overall sensitivity of the assay, 
particularly if substantial numbers of bacteria had been bound within the clumps, 
making the DNA unable to be extracted. Therefore, to determine the true sensitivity 
of the method, the kinetic studies need to be repeated so that fresh samples can be 
analysed. 
As elucidated in Chapter 4, the sensitivity of the PCR determines the 
downstream sensitivity of the Southern dot blots. We have shown that PCR of pure 
cultures and spiked PCs and RCCs allowed us to detect fewer bacteria than our 
preset limit of 10 3 CFU/mL. However, PCR of the frozen extracts was significantly 
less successful, with poor amplification occurring in samples containing below 10 7 
CFU/mL, making detection possible around the same time as product spoilage 
became evident. There are several possible explanations for the difference in the 
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sensitivity of detection obtained with the frozen samples compared to other sample 
types. As mentioned above, sample clotting may have reduced the actual number of 
bacteria from which DNA was extracted. Furthermore, it has previously been noted 
that freezing and long-term storage (more than 2 years in this case) of biological 
samples may lead to reduced sensitivity of PCR, or reduction of recoverable nucleic 
acid. Blood is also known to contain many PCR inhibitors (1, 62, 152), the 
concentration of which may have been increased by freezing or prolonged storage, or 
they may have been less efficiently removed by the extraction procedure. 
Interestingly, in some samples the QIAquick purification of RCC PCR products 
improved the sensitivity of detection by as much as two time-points earlier than their 
non-purified equivalents. This suggests that in some instances, there may have been 
inhibitors of DNA hybridisation in the frozen RCC samples. Further investigations 
should determine if these inhibitors are present only in samples frozen for long 
periods (thus explaining the need for additional purification of RCC samples in this 
study), or whether this observation applies to both frozen and non-frozen sample 
types. The bacteria may also have lysed during storage, causing the breakdown of 
their nucleic acid that may have undetectable by our large fragment PCR (but may 
have been detectable with a smaller target). Lastly, the 3 d interval between the 6 th 
and 9th  days of RCC storage (and subsequently 3 logs difference between the 
numbers of CFU recovered) may have also influenced the result. Had samples been 
taken between these days, detection may have been possible earlier, with a lower 
number of CFU present. Despite the disappointing sensitivity of PCR in this 
instance, and given that testing is most likely to occur at the time of sampling, these 
long-term frozen extracts do not accurately represent the 'real life' testing scenario. 
It is essential, therefore, that evaluation of the PCR be conducted on truly 
representative samples, including fresh aliquots taken during the kinetic experiment. 
We predict that this will significantly improve the sensitivity of detection, as there is 
no opportunity for the blood to coagulate and 'mask' the true number of organisms in 
a sample, nor will the freeze-thawing of samples have an influence. 
Fourteen oligoprobes were used successfully to detect a range of bacteria in 
pure cultures and spiked products. These were a collection of published and novel 
probes, which produced consistently specific results, regardless of the starting 
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material (Table 5.1a). They were further validated against the frozen extracts, and 
despite the lower PCR sensitivity, the specificity of the probes was the same as for 
the other sample types. On two occasions, it appeared that a positive blot had 
occurred where it was not expected (i.e., the 143+3 probe and the Spy3 probe in 
Table 5.1b). However, as this result was not reproducible, it is likely that an excess 
of probe or insufficient blocking of the membrane was responsible for the false-
positive result in this instance. Moreover, the strength of the signal from the true 
positive blots was considerably greater than the signals obtained with the false-
positive blots. 
In summary, a method by which bacteria can be detected and identified in blood 
products was developed. Further investigations with freshly collected samples must 
now occur to address the issue of the sensitivity of the assay. The extraction process 
is at the centre of the success of this procedure, and with fresh cultures and spiked 
products samples it was highly effective in yielding pure nucleic acid for PCR. 
Despite the short sequence of the oligoprobes and the small number of base pair 
differences in the 16S gene of many species, specific oligoprobes were able detect 
their targets with a high degree of specificity. It seems likely on balance that this 
method could be highly suitable for the detection of bacteria in blood products in a 
centralized testing facility immediately prior to their dispatch, although some 




Despite advances in transfusion practices, bacterial contamination of blood 
products continues to occur, and is currently acknowledged as the greatest infectious 
risk in transfusion medicine (63, 83, 116, 118, 175). The problem of bacterial 
contamination is characterised by several features. Bacteria may be introduced in 
relatively small numbers (1 to 10 CFU/mL) (7, 57, 78, 201) into products during 
collection (as a result of incomplete donor skin disinfection or asymptomatic 
bacteraemia) (19, 31, 79, 154), during processing (incomplete tubing seals) (212), or 
may be present in contaminated equipment (such as non-sterile product bags) (91, 
99). Storage conditions, which have been optimised for maximum prolonged 
preservation of products based on their cellular content, are highly suited for the 
survival and growth of many bacterial species to high numbers, without outward 
evidence of their presence. The diverse range of microorganisms involved, has 
added to the complexity of finding a solution the problem. The frequency at which 
contamination occurs, does not mirror the frequency of the reports of TTBS due to 
the acknowledged underreporting of incidents (103, 132). Furthermore, most 
recipients of blood products are immunocompromised in some way and therefore 
highly susceptible to infection. Prophylactic antibiotic treatment has not always been 
able to prevent TTBS in these patients, nor has treatment after the diagnosis of 
sepsis. Despite the evidence pointing towards the ongoing issue of bacterial 
contamination and the risks involved to patients, detection of bacterial contamination 
in blood products manufactured in Australia and many other locales is limited to 
quality control screening of a small proportion (eg. 1%) of the products. Moreover, 
bacterial screening of blood products relies on culture-based methods, which 
although automated, are expensive and can take several days for a definitive result. 
For these reasons, and the recognised need for more advanced rapid screening 
measures, the present study was undertaken. 
Although previous reports have examined the kinetics of bacteria in plasma 
rich products (PRP) (7, 31, 47, 73, 160, 201), these differ quite significantly from the 
buffy coat products used in Europe and Australia. The latter are increasingly 
preferred for their reduced alloimmunisation effects, but little is known as to how 
their composition affects bacterial outgrowth following contamination. Through 
analysis of epidemiological data obtained from the literature and the limited testing 
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of products at the ARCBS, four distinct groups of bacterial contaminants were 
identified: psychrophilic, environmental opportunists; mesophilic environmental 
opportunists; psychrophilic enterics, and skin flora (Aim 1, Chapter 3). Examination 
of representatives of these groups in stored buffy coat PCs (Figure 3.1) showed that 
each may proliferate to significant numbers following introduction of an inoculum of 
as few as 10 CFU/mL bacteria, which is comparable to what may be expected under 
natural conditions. Furthermore, the ability of these bacteria to proliferate to more 
than 105 CFU/mL (considered a clinical risk dose) (226) within 2 d of storage but 
without showing physical evidence until day 3 to 4 (107 to 109 CFU/mL, Figure 3.2) 
highlights the risk of relying upon spoilage for the identification of contaminated 
products. When compared with published data pertaining to bacterial growth in PCs 
obtained from PRP (7, 73, 160, 201), buffy coat PCs were at least equally susceptible 
to bacterial outgrowth, whilst in some instances (such as P. fluorescens) bacterial 
growth appeared to be more rapid in buffy coat products. This may be due to the 
reduced plasma content and lower WBC numbers in buffy coat products which may 
result in less restricted growth of bacteria, especially serum-sensitive strains. 
Interestingly, despite cases of sepsis involving Y. enterocolitica-contaminated 
PCs, previous reports found that this species is unable to survive or proliferate in 
such products (38, 205). Absence of growth has been attributed to the scarcity of 
free iron in PCs, and the inability of Y. enterocolitica to acquire iron from complexed 
sources such as haemoglobin due to a lack of siderophores. In this study, 
proliferation of Y. enterocolitica was observed in multiple experiments with PCs. 
The reproducibility of this finding with different PCs make it unlikely that increased 
free iron in products due to an abnormality in the donor or an increased number of 
RBCs in the finished blood components, produced this result. We therefore 
investigated the role of the virulence plasmid, pYV (which confers serum resistance 
and resistance to phagocytosis) (55), in the survival and proliferation of this species, 
using a plasmid-less variant of the original parent strain. These studies clearly 
demonstrated that only the pYV-possessing strain was able to survive and proliferate 
in PCs (Figure 3.5a), suggesting that Y. enterocolitica strains used in previous studies 
had spontaneously lost the plasmid (a common occurrence) and as a consequence, 
were susceptible to killing by serum and ingestion by phagocytes. There is also 
154 
some evidence that the 03 serotype of Y. enterocolitica may have a greater resistance 
to antimicrobial killing than the 08 serotype (most commonly found in the US, and 
predominantly used in previous PRP spiking studies). The prevalence of the 03 
serotype and its relative resistance to killing may provide a partial explanation for the 
predominance of this bacterium in reports of TTBS in Australia and New Zealand, 
although there are no data to show that Y. enterocolitica 03 is more resistant to 
killing in buffy coat PCs than Y. enterocolitica 08 (38, 204). 
The psychrophilic species freely proliferated in RCCs under refrigerated 
conditions to reach clinically significant numbers several days before spoilage 
became evident (Figure 3.3 and 3.4). Contrary to our findings with PCs, the growth 
of both pYV+ and pYV- strains was similar (Figure 3.5b), indicating that pYV is not 
necessary for bacterial survival in this product. As the number of WBCs and the 
amount of natural plasma remaining in PCs and RCCs are comparable, an 
explanation for the growth of the pYV- strain may be (1) that yop effector genes are 
not expressed at low temperatures (102) or (2) that any antimicrobial activity in 
RCCs is slowed or eliminated under refrigeration. This could also explain the lack of 
clearance of non-proliferating bacteria (such as S. aureus) from the RCCs. The 
persistence of small numbers of bacteria (5 CFU/mL) on its own may be considered 
unimportant, as these are generally not considered to pose a significant risk to 
patients. However, there have been instances of TTBS involving S. aureus and other 
non-psychrophilic species that have resulted in patient deaths due to contaminated 
RCCs (116, 164, 216, 217). This raises the question of what numbers of bacteria are 
clinically relevant, particularly with immunocompromised recipients. It has also yet 
to be determined whether the risk in these instances lies with fragmented bacterial 
remnants (e.g. from bacteria that were introduced into blood products at higher 
concentrations than 5 CFU/mL and were subsequently killed during storage), or with 
bacterial proliferation in the transfusion recipient. The survival of S. aureus in this 
instance (whilst reportedly causing TTBS) poses the question, does the clinically 
significant number of bacteria vary with different bacterial strains? This relates to 
the production of superantigens, endotoxin and exotoxins (7, 46, 134-136, 140) by 
different bacterial species, which may be present in excess with few viable 
microorganisms. Certainly the majority of bacterial species found in blood products 
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are skin flora (such as coagulase negative staphylococci) or Gram-positive anaerobes 
(such as Corynebacterium and Propionibacterium spp.), which despite their linkage 
with human disease, are often dismissed as insignificant as transfusion risks. 
As a bacterial detection method should be useful for all product types, and all 
groups of bacteria tested were able to proliferate in either or both of PCs and RCCs, 
all contaminants were considered significant and hence important for detection. 
Despite the well known risks posed to patients by bacterially contaminated 
blood products, it is only in the last two years with the implementation of American 
Association of Blood Banks standards for the mandatory bacterial screening of PCs, 
that the issue has begun to be addressed. The ARCBS has recognised the need for 
new ways to approach the problem of bacterial contamination, and this study (Aim 2) 
was designed with the intention of developing a novel rapid detection method. 
In accordance with the shift of technology towards detection of viral 
contaminants at the ARCBS using nucleic acid targeting (NAT testing), molecular 
methods that could be employed using existing infrastructure at the ARCBS were 
investigated. Preliminary data revealed that that the blood products from which 
DNA template must be extracted (particularly RCCs) are complex and dense 
materials, and that the bacteria (particularly the Gram-positive species) were difficult 
to lyse. Extraction kits recommended for such applications were found to be 
unsuitable, resulting in DNA yields that were lower than desired, or highly 
contaminated with proteinaceous residues, or that the protocol was unable to 
efficiently lyse the bacteria within a convenient timeframe. Furthermore, the target 
sample volume of 1 mL was unable to be processed due to the considerable amount 
of cellular debris generated from RCCs. Subsequently. a novel extraction technique 
was developed that used a combination of bead beating and spin column cleanup to 
give purified template from both Gram-positive and Gram-negative species in 1 mL 
PC and RCC samples, which could be detected by PCR using as little as a few fg per 
sample (at both species-specific and universal 16S PCR levels). The sensitivity of 
the 1.4 kb 16S universal PCR was equivalent to that obtained with a 
Y. enterocolitica-specific PCR in blood products (70). Furthermore, this PCR proved 
a powerful tool for discriminating between contaminated and non-contaminated 
blood products, and was not subject to false-positive results such as those which 
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occur frequently when smaller-sized 16S DNA fragments are targeted. 
Discrimination between live and dead bacteria can also be made with this assay, as 
the nucleic acid of non-viable microorganisms is usually below the target size of this 
assay, and should therefore not be amplifiable. Although there have been reports of 
methods to detect bacterial rRNA in blood products directly (without the need of 
PCR) using oligoprobes (33, 34, 47, 170), these have thus far failed to achieve a 
sensitivity greater than 104 CFU/mL, and the process is too slow for pre-transfusion 
testing (170). Furthermore, the presence of nucleic acid from non-viable 
microorganisms or from the blood products themselves (129) and the ubiquitous 
nature of bacterial nucleic acid may give rise to false-positive results. Another 
advantage of using the developed method with universal 16S products, is that yet to 
be identified species that may pose a risk to transfusion recipients in future can be 
detected with without additional test development. 
Comparison of standard PCR and real-time formats for their ability to detect 
bacterial contamination in blood products using universal targets showed that the 
standard PCR format provided more sensitive, specific and consistent results than 
real-time PCR. Whether the sensitivity of the real-time PCR was affected by a high 
background fluorescence of the SYBR green binding non-specifically to residual 
protein in the samples (i.e., the template must be of a higher purity for real-time PCR 
than for standard PCR, due to the optical nature of the detection mechanism and the 
fact that some protein was visualised in several samples during electrophoresis) has 
yet to be established, but appears likely. This issue may be resolved in future 
through further improvement of the template purification process. The use of 
specific probes rather than non-specific reporters such as SYBR green may also 
improve the sensitivity and specificity of the assay, although the issue of 
contaminating environmental DNA (giving rise to false-positive results) must also be 
addressed before this method can be considered. Until all reagents and plasticware 
can be provided entirely free of environmental DNA, this will continue to be an issue 
for universal 16S real-time PCR. 
Following amplification of the conserved 1.4 kb 16S target, we showed that 
identification of the contaminating species was possible using oligoprobes and 
Southern dot blot hybridisation. Dot blotting has the advantage of obviating gel 
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transfer (necessary with electrophoresed products), thus speeding up the detection 
process overall. Using the DIG Easy-Hyb system, the entire process could be 
completed in just a few hours (plus PCR time), which is within the desired timeframe 
of testing on the day before or the same day the product is despatched (Chapter 5). 
The speed of the assay may further be improved with optimisation of the assay to 
reduce detection time (such as reducing the hybridisation time to 30 min, as 
suggested by the manufacturer). Furthermore, this study has shown that it may be 
possible to combine multiple probes (Figure 5.3) to eliminate the need for a separate 
probe for each target. In smaller blood banks, the minimum requirement of 
screening lies with a simple yes (contaminated) or no (sterile) answer utilising the 
universal probe only, perhaps with subsequent identification of the bacterial species 
by a reference laboratory. 
An alternative to the binary yes/no approach with the detection method 
described may utilise a multiplexed solution of universal, Gram-negative and Gram-
positive probes. This might be particularly useful in a diagnostic setting to direct 
patient therapy. A similar approach was taken by Verax Biomedical (Worcester, 
MA.) (110), who recently reported an assay that could detect 10 3 to 104 CFU/mL of 
bacteria in PCs using gold-conjugated antibodies targeted to the lipopolysaccharide 
of Gram-negative bacteria and the lipoteichoic acid of Gram-positive bacteria. 
However this method and other similar assays (such as Immunetics Inc with their 
fluorescently—labelled peptidoglycan targeted antibody system) (16) are limited to 
the detection of bacteria in PCs only. Furthermore, these methods may detect 
bacterial fragments in the absence of live, whole microorganisms. Although the 
method developed in his study is comparatively slower than these antibody-based 
methods, it has the advantage of being applicable to both PCs and RCCs, and 
preferentially targeting viable bacteria. 
The PCR and oligoprobing system developed during the course of this study 
was highly sensitive and specific with both spiked blood products and pure bacterial 
extracts, and is therefore likely to be applicable and useful for other sample types. 
Further validation of the proposed method of detection (Aim 3 of this thesis, the 
results of which were collated in Chapter 5) involved in a comparison of the spiked 
blood product results with those obtained for bacterial DNA extracted from frozen 
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samples collected from the kinetic assays (Chapter 3). However, whilst the 
specificity of the probes was consistent between sample types, the sensitivity of the 
PCR using template extracted from the frozen samples was lower than for the spiked 
samples (Table 5.1). As the screening of blood products is proposed to occur the day 
before release, it is highly unlikely that the samples for testing will be frozen 
(certainly not for two years as in this study). Further experiments with freshly 
collected kinetic samples should be able to resolve these concerns. We anticipate 
with the repetition of the detection assays using fresh samples, the effects of the 
freezing (and DNA degradation) will be significantly reduced or eliminated. This 
hypothesis is supported by reports that freezing interferes with molecular detection of 
nucleic acid in clinical samples. Even if these fresh samples produce results of 
reduced sensitivity similar to the frozen samples, the assay may still be useful. As 
screening is proposed for the day before or the day of product despatch (average of 
RCCs is 28 d, and of PCs is 4 to 5 d), (12) this may be sufficiently late for these 
products to contain bacterial numbers above the sensitivity of detection. The 
findings of Chapter 3 suggest that proliferating bacteria will be between 10 7 and 109 
CFU/mL in buffy coat blood products after storage for this length of time. 
Moreover, a highly sensitive assay (<10 2 CFU/mL) may result in all blood products 
being found to contain bacterial DNA (particularly in the case of assays targeting 
short ribosomal sequences or bacterial fragments, such as LPS or lipoteichoic acid). 
Would it be necessary to discard all of these? Although these questions are beyond 
the scope of this study, the current shortage of blood products resulting from short 
product shelf-life (particularly PCs), and the deferral of many potential donors (e.g., 
due to malaria risks (69, 144) is well documented. 
Another feature of the approach developed here, is the possibility for it to be 
automated for high-throughput of samples such as required by the blood banking 
industry. Furthermore, the use of oligoprobes to detect DNA is not unlike the 
process involved in microarray analysis, which has been proposed as the future of 
blood testing (155). Although this process is predominantly used for gene expression 
studies, it has also been used as a bacterial detection method, and may provide a 
powerful means for high-throughput screening in future (40, 41, 50, 207). 
Furthermore, PCR conducted directly on the microarray slide may enable the entire 
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amplification and detection process to be carried out without multiple handling steps 
(48, 115, 186, 223). Microarray technology is currently comparatively expensive in 
terms of equipment and reagents. However, as the technology is increasingly 
adopted, the costs involved should decrease as happened with PCR (155). 
Furthermore, the ability to process thousands of samples on a single glass slide with 
small volumes of reagent should also reduce the cost. It has also been proposed to 
combine blood typing, viral screening and bacterial screening, to confirm the nature 
of the product contents and ensure its sterility (155). This illustrates a strength of the 
approach used in this detection method, namely its versatility in terms of sample 
types and target species detected, with potential for adaptation to other platforms 
such as microarray. 
In summary, the 'zero risk' approach taken to blood banking has increased 
awareness of the problem of bacterial contamination of blood products, and 
emphasised the need for ways to detect this rapidly. This study found that a diverse 
array of bacterial contaminants found in blood products can survive and proliferate in 
both buffy coat PCs and RCCs. Further to this, detection of these bacterial 
pathogens can be achieved rapidly and sensitively by targeting conserved 16S rDNA 
sequences, with further identification provided by hybridisation with oligoprobes. 
As yet unidentified bacterial contaminants may also be detected in this way. 
Although further validation of this technique is required, this approach may also be 
useful beyond the transfusion setting, in diagnostic medicine, or quality control of 
food or other substances. Furthermore, there is potential for using this detection 
method as the basis for further novel detection assays, such as microarray screening 
which should allow more samples to be processed in a shorter time-period, and 
should become increasingly attractive as the cost of the technology decreases. 
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